Anti-tissue factor antibodies, antibody-drug conjugates and related methods
By developing antibodies and antibody-drug conjugates specifically binding to human tissue factor (TF) antibodies and antibody-drug conjugates, the angiogenesis and inflammation caused by TF overexpression were solved, and effective inhibition of cancer and other diseases was achieved while maintaining thrombin production. normal level.
Patent Information
- Application Number
- CN202411131788.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-08-02
- Filing Date
- 2019-01-04
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively target angiogenesis and inflammation problems caused by overexpression of tissue factors (TFs) in cancer and other diseases, and traditional antibodies may interfere with the clotting process and affect thrombin production.
A specific binding human tissue factor (TF) antibody and antibody-drug conjugate was developed to inhibit FVIIa-dependent signaling by binding to different binding sites of TF and showed a better performance in live cell staining assays. Low inhibition or permits thrombin production while not interfering with the function of TF:FVIIa.
A specific inhibition of TF overexpression is achieved, reducing the risk of angiogenesis in cancer and other diseases, while maintaining normal levels of thrombin production and avoiding interference from the clotting process.
Smart Images

Figure CN118955720A_ABST
Abstract
Description
[0001] This application is a divisional application of invention patent application No. 201980016636.6, with an application date of January 4, 2019 and an invention name of “Anti-tissue factor antibodies, antibody-drug conjugates and related methods”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Application Nos. 62 / 613,545, filed January 4, 2018, 62 / 613,564, filed January 4, 2018, 62 / 646,788, filed March 22, 2018, 62 / 713,797, filed August 2, 2018, and 62 / 713,804, filed August 2, 2018, each of which is hereby incorporated by reference herein in its entirety.
[0004] Sequence Listing
[0005] This application contains a sequence listing that has been submitted through EFS and is hereby incorporated by reference in its entirety. The ASCII copy was created on February 28, 2019, is named 41904WO_CRF_sequencelisting.txt, and is 382,993 bytes in size. Background Art
[0006] Blood coagulation involves a series of complex processes that cause blood coagulation. Tissue factor (TF) plays an important role in these coagulation processes. TF is a cell surface receptor for the serine protease factor VIIa (FVIIa). The TF / FVIIa complex catalyzes the conversion of inactive protease factor X (FX) into active protease factor Xa (FXa). FXa and its cofactor FVa form the prothrombinase complex, which generates thrombin from prothrombin. Thrombin converts soluble fibrinogen into insoluble fibrin chains and catalyzes many other coagulation-related processes.
[0007] TF is overexpressed in many types of solid tumors. In cancer, TF / FVIIa signaling can support angiogenesis, tumor progression, and metastasis. Increased TF expression can also induce inflammation and / or angiogenesis in many other diseases, including wet age-related macular degeneration (AMD) and diabetic retinopathy. Summary of the Invention
[0008] Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates, and related methods.
[0009] In one aspect, provided herein is an isolated human antibody that binds to the extracellular domain of human tissue factor (TF), wherein the antibody binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FVIIa.
[0010] In some embodiments, (1) is combined with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA) compared to a reference antibody having the same sequence as SEQ ID NO: 810, and (2) the binding between the isolated antibody and the extracellular domain of a variant TF comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0011] In some embodiments, (1) is combined with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibody inhibits human thrombin generation as determined by a thrombin generation assay (TGA) to a lesser extent than a reference antibody having the same sequence as that shown in FIG5 , and (2) the binding between the isolated antibody and the extracellular domain of a variant TF comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0012] In some embodiments, (1) is combined with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibody allows human thrombin generation to a greater extent as determined by a thrombin generation assay (TGA) compared to a reference antibody having the sequence shown in SEQ ID NO: 810, and (2) the binding between the isolated antibody and the variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0013] In some embodiments, (1) is combined with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibody inhibits human thrombin generation as determined by a thrombin generation assay (TGA) by a lesser amount than a reference antibody having the sequence shown in SEQ ID NO: 810, and (2) the binding between the isolated antibody and the extracellular domain of TF comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0014] In some embodiments, (1) is combined with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibody allows human thrombin generation in greater amounts as determined by a thrombin generation assay (TGA) compared to a reference antibody having the sequence shown in SEQ ID NO: 810, and (2) the binding between the isolated antibody and the extracellular domain of TF comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0015] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784.
[0016] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877.
[0017] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883.
[0018] In some embodiments, the V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibodies did not inhibit human thrombin generation as determined by a thrombin generation assay (TGA) compared to a reference antibody of the same sequence.
[0019] In some embodiments, the V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibodies inhibit human thrombin generation as determined by a thrombin generation assay (TGA) to a lesser extent than a reference antibody having the same sequence as that of the thrombinase inhibitor.
[0020] In some embodiments, the V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibodies allow human thrombin generation to a greater extent than a reference antibody of the same sequence as described above, as determined by a thrombin generation assay (TGA).
[0021] In some embodiments, the V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibodies inhibit human thrombin generation as determined by a thrombin generation assay (TGA) by a lesser amount than a reference antibody having the same sequence as that of the thrombinase inhibitor.
[0022] In some embodiments, the V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibodies allow human thrombin generation as determined by thrombin generation assay (TGA) in greater amounts than a reference antibody of the same sequence.
[0023] In some embodiments, antibody does not suppress the human thrombin determined by thrombin generation assay (TGA) and generates. In some embodiments, compared with isotype control, antibody does not reduce the thrombin peak value (peak value IIa) on the thrombin generation curve. In some embodiments, compared with isotype control, antibody does not increase the time (ttPeak) from the start of measuring to the thrombin peak value on the thrombin generation curve. In some embodiments, compared with isotype control, antibody does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve. In some embodiments, antibody allows the human thrombin determined by thrombin generation assay (TGA) to generate. In some embodiments, compared with isotype control, antibody keeps the thrombin peak value (peak value IIa) on the thrombin generation curve. In some embodiments, compared with isotype control, antibody keeps the time (ttPeak) from the start of measuring to the thrombin peak value on the thrombin generation curve. In some embodiments, compared with isotype control, antibody retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve.
[0024] In some embodiments, the antibody binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX.In some embodiments, the antibody does not interfere with the ability of TF:FVIIa to convert FX to FXa.
[0025] In some embodiments, the antibody does not compete with human FVIIa for binding to human TF.
[0026] In some embodiments, the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); allows human thrombin generation as determined by a thrombin generation assay (TGA); binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; does not interfere with the ability of TF:FVIIa to convert FX to FXa; and does not compete with FVIIa for binding to human TF.
[0027] In some embodiments, the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; allows human thrombin generation as determined by a thrombin generation assay (TGA); retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX; does not interfere with the ability of TF:FVIIa to convert FX to FXa; and does not compete with FVIIa for binding to human TF.
[0028] In some embodiments, the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); does not reduce the thrombin peak (Peak IIa) on the thrombin generation curve compared to an isotype control; does not increase the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to an isotype control; does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; allows human thrombin generation as determined by a thrombin generation assay (TGA); maintains the thrombin peak on the thrombin generation curve (Peak IIa) compared to the isotype control; maintains the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to the isotype control; retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to the isotype control; binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX; does not interfere with the ability of TF:FVIIa to convert FX to FXa; and does not compete with FVIIa for binding to human TF.
[0029] In some embodiments, the antibody inhibits FVIIa-dependent TF signaling.
[0030] In some embodiments, the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is K149N.
[0031] In some embodiments, the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is K68N.
[0032] In some embodiments, the binding of the isolated antibody to a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay. In some embodiments, the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 are N171H and T197K.
[0033] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 1 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 1 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0034] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 39 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 38 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0035] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0036] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 146 to 158 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 151 to 163 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0037] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159 to 219 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 224 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0038] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159 to 189 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 194 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0039] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0040] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 167 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 172 to 179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0041] In some embodiments, the binding between the isolated antibody and the extracellular domain of rat TF (in which amino acid residues 141 to 194 of the sequence set forth in SEQ ID NO: 838 are substituted with amino acid residues 136 to 189 of the extracellular domain of human TF set forth in SEQ ID NO: 810) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0042] In some embodiments, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay, the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; and the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 1 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 1 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 838. The isolated antibody binds to the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810, wherein amino acid residues 39 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 38 to 76 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838, which is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the isolated antibody binds to the extracellular domain of human TF with the sequence set forth in SEQ ID NO: 810, wherein amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838, which is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the isolated antibody binds to the extracellular domain of human TF with the sequence set forth in SEQ ID NO: 810, wherein amino acid residues 146 to 158 of the sequence set forth in SEQ ID NO: NO:838, in which amino acid residues 151 to 163 of the extracellular domain of rat TF are substituted with amino acid residues 151 to 163 of the extracellular domain of rat TF with the sequence shown in SEQ ID NO:838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO:810; and the binding between the isolated antibody and the extracellular domain of rat TF (in which amino acid residues 141 to 194 of the sequence shown in SEQ ID NO:838 are substituted with amino acid residues 136 to 189 of the extracellular domain of human TF with the sequence shown in SEQ ID NO:810) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO:810.In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is K149N; and the mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is K68N.
[0043] In some embodiments, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay, the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the isolated antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; and the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 1 to 77 of the sequence set forth in SEQ ID NO: 810 are replaced by SEQ ID NO: 810). The binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 838 (in which amino acid residues 1 to 76 of the extracellular domain of rat TF are substituted by amino acid residues 38 to 76 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 39 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted by amino acid residues 38 to 76 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted by amino acid residues 99 to 112 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; The binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO:810) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO:810;The binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159 to 219 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 224 of the extracellular domain of rat TF of the sequence set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence set forth in SEQ ID NO: 810; the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159 to 189 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 194 of the extracellular domain of rat TF of the sequence set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence set forth in SEQ ID NO: 810; the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 194 of the extracellular domain of rat TF of the sequence set forth in SEQ ID NO: The binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 838 (in which amino acid residues 164 to 179 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838 are substituted) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 167 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 172 to 179 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; and the binding between the isolated antibody and the extracellular domain of rat TF (in which amino acid residues 141 to 194 of the sequence set forth in SEQ ID NO: 838 are substituted with amino acid residues 136 to 189 of the extracellular domain of human TF with the sequence set forth in SEQ ID NO: 810) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is K149N; the mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is K68N; and the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 are N171H and T197K.
[0044] In some embodiments, the antibody binds to cynomolgus monkey TF. In some embodiments, the antibody binds to mouse TF. In some embodiments, the antibody binds to rabbit TF. In some embodiments, the antibody binds to porcine TF.
[0045] In some embodiments, the antibody reduces lesion size in a porcine choroidal neovascularization (CNV) model.
[0046] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); and (b) binds to a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay, less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810. In some embodiments, the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 are N171H and T197K.
[0047] In some embodiments, the antibody: (a) allows for human thrombin generation as determined by a thrombin generation assay (TGA); and (b) binds to a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay, less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810. In some embodiments, the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 are N171H and T197K.
[0048] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; and (c) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO:810 are N171H and T197K.
[0049] In some embodiments, the antibody: (a) permits human thrombin generation as determined by a thrombin generation assay (TGA); (b) binds to a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; and (c) binds to a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO:810 are N171H and T197K.
[0050] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) binds to cynomolgus monkey TF; (c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; and (d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO:810 are N171H and T197K.
[0051] In some embodiments, the antibody: (a) permits human thrombin generation as determined by a thrombin generation assay (TGA); (b) binds to cynomolgus monkey TF; (c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; and (d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO:810 are N171H and T197K.
[0052] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) allows human thrombin generation as determined by a thrombin generation assay (TGA); (c) binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; (d) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (e) does not compete with FVIIa for binding to human TF; (f) inhibits FVIIa-dependent TF signaling; (g) binds to cynomolgus monkey TF; (h) binds to mouse TF; and (i) binds to rabbit TF.
[0053] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (c) allows human thrombin generation as determined by a thrombin generation assay (TGA); (d) retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; (f) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (g) does not compete with FVIIa for binding to human TF; (h) inhibits FVIIa-dependent TF signaling; (i) binds to cynomolgus monkey TF; (j) binds to mouse TF; and (k) binds to rabbit TF.
[0054] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the thrombin peak value (Peak IIa) on the thrombin generation curve compared to an isotype control; (c) does not increase the time from the start of the assay to the thrombin peak value on the thrombin generation curve (ttPeak) compared to an isotype control; (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by a thrombin generation assay (TGA); (f) maintains the thrombin peak value (Peak Il) on the thrombin generation curve compared to an isotype control. Ia); (g) retains the time from the start of the assay to the peak thrombin level on the thrombin generation curve (ttPeak) compared to an isotype control; (h) retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (i) binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (k) does not compete with FVIIa for binding to human TF; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus monkey TF; (n) binds to mouse TF; and (o) binds to rabbit TF.
[0055] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) allows human thrombin generation as determined by a thrombin generation assay (TGA); (c) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX; (d) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (e) does not compete with FVIIa for binding to human TF; (f) inhibits FVIIa-dependent TF signaling; (g) binds to cynomolgus monkey TF; (h) binds to mouse TF; (i) binds to rabbit TF; (j) binds to porcine TF; and (k) reduces lesion size in a porcine choroidal neovascularization (CNV) model.
[0056] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (c) allows human thrombin generation as determined by a thrombin generation assay (TGA); (d) retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; (f) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (g) does not compete with FVIIa for binding to human TF; (h) inhibits FVIIa-dependent TF signaling; (i) binds to cynomolgus monkey TF; (j) binds to mouse TF; (k) binds to rabbit TF; (l) binds to porcine TF; and (m) reduces lesion size in a porcine choroidal neovascularization (CNV) model.
[0057] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the thrombin peak (peak IIa) on the thrombin generation curve compared to an isotype control; (c) does not increase the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to an isotype control; (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by a thrombin generation assay (TGA); (f) maintains the thrombin peak (peak IIa) on the thrombin generation curve compared to an isotype control; (g) maintains the time from the start of the assay to the thrombin peak on the thrombin generation curve compared to an isotype control. (h) retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve (AUC) compared to an isotype control; (i) binds to human TF at a human TF binding site distinct from the human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (k) does not compete with FVIIa for binding to human TF; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus monkey TF; (n) binds to mouse TF; (o) binds to rabbit TF; (p) binds to porcine TF; and (q) reduces lesion size in a porcine choroidal neovascularization (CNV) model.
[0058] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the thrombin peak value (Peak IIa) on the thrombin generation curve compared to an isotype control; (c) does not increase the time from the start of the assay to the thrombin peak value on the thrombin generation curve (ttPeak) compared to an isotype control; (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by a thrombin generation assay (TGA); (f) maintains the thrombin peak value (Peak IIa) on the thrombin generation curve compared to an isotype control; (g) maintains the time (ttPeak) from the start of the assay to the thrombin peak value on the thrombin generation curve compared to an isotype control. k); (h) retains endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve (AUC) compared to an isotype control; (i) binds to human TF at a human TF binding site distinct from the human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (k) does not compete with FVIIa for binding to human TF; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus monkey TF; (n) binds to mouse TF; (o) binds to rabbit TF; (p) binds to porcine TF; (q) reduces lesion size in a porcine choroidal neovascularization (CNV) model; (r) the isolated antibody has a similar affinity to a fragment comprising SEQ ID NO: 1 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay. (s) the binding of the isolated antibody to a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding of the isolated antibody to the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay; (t) the binding of the isolated antibody to a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding of the isolated antibody to the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay;(u) the isolated antibody binds to the extracellular domain of human TF (in which amino acid residues 1 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 1 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay; (v) the isolated antibody binds to the extracellular domain of human TF (in which amino acid residues 39 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 38 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay; (w) the isolated antibody binds to the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay that is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; (x) the isolated antibody binds to the extracellular domain of human TF (in which amino acid residues 146 to 158 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 151 to 163 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay that is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 (y) the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159 to 219 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 224 of the rat TF extracellular domain set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay;(z) the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 159 to 189 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 194 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay; (aa) the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 159 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay; and (cc) wherein the isolated antibody has greater binding to the extracellular domain of rat TF (in which amino acid residues 141 to 194 of the sequence set forth in SEQ ID NO: 838 are substituted with amino acid residues 136 to 189 of the extracellular domain of human TF set forth in SEQ ID NO: 810) than to the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay. 50% of the binding between the extracellular domains of TF with the sequence shown in NO:810.
[0059] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the thrombin peak value (Peak IIa) on the thrombin generation curve compared to an isotype control; (c) does not increase the time from the start of the assay to the thrombin peak value on the thrombin generation curve (ttPeak) compared to an isotype control; (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by a thrombin generation assay (TGA); (f) maintains the thrombin peak value (Peak IIa) on the thrombin generation curve compared to an isotype control; (g) maintains the time (ttPeak) from the start of the assay to the thrombin peak value on the thrombin generation curve compared to an isotype control. k); (h) retains endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve (AUC) compared to an isotype control; (i) binds to human TF at a human TF binding site distinct from the human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (k) does not compete with FVIIa for binding to human TF; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus monkey TF; (n) binds to mouse TF; (o) binds to rabbit TF; (p) binds to porcine TF; (q) reduces lesion size in a porcine choroidal neovascularization (CNV) model; (r) the isolated antibody has a similar affinity to a fragment comprising SEQ ID NO: 1 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay. (s) the binding between the isolated antibody and a variant TF extracellular domain comprising the mutation K68N of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay; (t) the binding between the isolated antibody and a variant TF extracellular domain comprising the mutations N171H and T197K of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay;(u) the isolated antibody binds to the extracellular domain of human TF (in which amino acid residues 1 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 1 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay; (v) the isolated antibody binds to the extracellular domain of human TF (in which amino acid residues 39 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 38 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay; (w) the isolated antibody binds to the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay that is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; (x) the isolated antibody binds to the extracellular domain of human TF (in which amino acid residues 146 to 158 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 151 to 163 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay that is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 (y) the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159 to 219 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 224 of the rat TF extracellular domain set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay;(z) the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 159 to 189 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 194 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay; (aa) the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 159 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay; and (cc) wherein the isolated antibody has greater binding to the extracellular domain of rat TF (in which amino acid residues 141 to 194 of the sequence set forth in SEQ ID NO: 838 are substituted with amino acid residues 136 to 189 of the extracellular domain of human TF set forth in SEQ ID NO: 810) than to the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay. 50% of the binding between the extracellular domains of TF with the sequence shown in NO:810.
[0060] In some embodiments, the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0061] In some embodiments, the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0062] In some embodiments, the antibody competes for binding to human TF with the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0063] In some embodiments, the antibody binds to the same epitope of human TF that is bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0064] In some embodiments, the antibody binds to the same epitope of human TF that is bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0065] In some embodiments, the antibody binds to the same epitope of human TF that is bound by the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0066] In some embodiments, the antibody comprises all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the following antibodies: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea. In some embodiments, the three heavy chain CDRs and the three light chain CDRs are identified using Kabat, Chothia, AbM, Contact, or IMGT numbering.
[0067] In some embodiments, the antibody comprises all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the antibody designated 25A, the antibody designated 25A5-T, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0068] In some embodiments, the antibody comprises all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0069] In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5-T. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43B1. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43B7. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43D. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43D7. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43D8. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43E. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43Ea.
[0070] In some embodiments, the antibody comprises V of SEQ ID NO: 113 H Sequence and V of SEQ ID NO: 114 L In some embodiments, the antibody comprises V of SEQ ID NO: 151. H Sequence and V of SEQ ID NO: 152 L In some embodiments, the antibody comprises V of SEQ ID NO: 189. H Sequence and V of SEQ ID NO: 190 L In some embodiments, the antibody comprises V of SEQ ID NO: 836. H Sequence and V of SEQ ID NO:837L In some embodiments, the antibody comprises a V sequence of SEQ ID NO: 227. H Sequence and V of SEQ ID NO: 228 L In some embodiments, the antibody comprises V of SEQ ID NO: 265. H Sequence and V of SEQ ID NO: 266 L In some embodiments, the antibody comprises V of SEQ ID NO: 303. H Sequence and V of SEQ ID NO:304 L In some embodiments, the antibody comprises V of SEQ ID NO: 455. H Sequence and V of SEQ ID NO:456 L In some embodiments, the antibody comprises V of SEQ ID NO: 493. H Sequence and V of SEQ ID NO: 494 L In some embodiments, the antibody comprises V of SEQ ID NO: 531. H Sequence and SEQ ID NO: 532 V L In some embodiments, the antibody comprises V of SEQ ID NO: 569. H Sequence and V of SEQ ID NO:570 L In some embodiments, the antibody comprises V of SEQ ID NO: 607. H Sequence and V of SEQ ID NO: 608 L In some embodiments, the antibody comprises V of SEQ ID NO: 645. H Sequence and V of SEQ ID NO: 646 L In some embodiments, the antibody comprises V of SEQ ID NO: 683. H Sequence and V of SEQ ID NO: 684 L In some embodiments, the antibody comprises V of SEQ ID NO: 721 H Sequence and V of SEQ ID NO:722 L sequence.
[0071] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802.
[0072] In some embodiments, the antibody comprises V of SEQ ID NO: 763. H Sequence and V of SEQ ID NO:764 L In some embodiments, the antibody comprises V of SEQ ID NO: 868. H Sequence and V of SEQ ID NO:869 L In some embodiments, the antibody comprises V of SEQ ID NO: 870 HSequence and V of SEQ ID NO:871 L In some embodiments, the antibody comprises V of SEQ ID NO: 769. H Sequence and V of SEQ ID NO: 770 L sequence.
[0073] In some embodiments, the antibodies include: an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, an antibody designated 25G9, an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0074] In some embodiments, the antibody comprises: an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, or an antibody designated 25G9.
[0075] In some embodiments, the antibody comprises: an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0076] In some embodiments, the antibody consists of an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, an antibody designated 25G9, an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0077] In some embodiments, the antibody consists of an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, or an antibody designated 25G9.
[0078] In some embodiments, the antibody consists of an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0079] In another aspect, provided herein is an isolated antibody comprising all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the following antibodies: antibody designated 25A, antibody designated 25A3, antibody designated 25A5, antibody designated 25A5-T, antibody designated 25G, antibody designated 25G1, antibody designated 25G9, antibody designated 43B, antibody designated 43B1, antibody designated 43B7, antibody designated 43D, antibody designated 43D7, antibody designated 43D8, antibody designated 43E, or antibody designated 43Ea.
[0080] In some embodiments, the antibody is a human antibody, a humanized antibody, or a chimeric antibody.
[0081] In some embodiments, the three heavy chain CDRs and the three light chain CDRs are identified using Kabat, Chothia, AbM, Contact, or IMGT numbering.
[0082] In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0083] In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5-T. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9.
[0084] In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0085] In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43B. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43B1. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43B7. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43D. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43D7. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43D8. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43E. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43Ea.
[0086] In some embodiments, the antibody comprises V of SEQ ID NO: 113 H Sequence and V of SEQ ID NO: 114 L In some embodiments, the antibody comprises V of SEQ ID NO: 151. H Sequence and V of SEQ ID NO: 152 L In some embodiments, the antibody comprises a V sequence of SEQ ID NO: 189. H Sequence and V of SEQ ID NO: 190 L In some embodiments, the antibody comprises V of SEQ ID NO: 836. H Sequence and V of SEQ ID NO:837 L In some embodiments, the antibody comprises a V sequence of SEQ ID NO: 227. H Sequence and V of SEQ ID NO: 228 L In some embodiments, the antibody comprises V of SEQ ID NO: 265. H Sequence and V of SEQ ID NO: 266 LIn some embodiments, the antibody comprises V of SEQ ID NO: 303. H Sequence and V of SEQ ID NO:304 L In some embodiments, the antibody comprises V of SEQ ID NO: 455. H Sequence and V of SEQ ID NO:456 L In some embodiments, the antibody comprises V of SEQ ID NO: 493. H Sequence and V of SEQ ID NO: 494 L In some embodiments, the antibody comprises V of SEQ ID NO: 531. H Sequence and SEQ ID NO: 532 V L In some embodiments, the antibody comprises V of SEQ ID NO: 569. H Sequence and V of SEQ ID NO:570 L In some embodiments, the antibody comprises V of SEQ ID NO: 607. H Sequence and V of SEQ ID NO: 608 L In some embodiments, the antibody comprises V of SEQ ID NO: 645. H Sequence and V of SEQ ID NO: 646 L In some embodiments, the antibody comprises V of SEQ ID NO: 683. H Sequence and V of SEQ ID NO: 684 L In some embodiments, the antibody comprises V of SEQ ID NO: 721 H Sequence and V of SEQ ID NO:722 L sequence.
[0087] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802.
[0088] In some embodiments, the antibody comprises V of SEQ ID NO: 763. H Sequence and V of SEQ ID NO:764 L In some embodiments, the antibody comprises V of SEQ ID NO: 868. H Sequence and V of SEQ ID NO:869 L In some embodiments, the antibody comprises V of SEQ ID NO: 870 HSequence and V of SEQ ID NO:871 L In some embodiments, the antibody comprises V of SEQ ID NO: 769. H Sequence and V of SEQ ID NO: 770 L sequence.
[0089] In some embodiments, the antibodies include: an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, an antibody designated 25G9, an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0090] In some embodiments, the antibody comprises: an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, or an antibody designated 25G9.
[0091] In some embodiments, the antibody comprises: an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0092] In some embodiments, the antibody consists of an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, an antibody designated 25G9, an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0093] In some embodiments, the antibody consists of an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, or an antibody designated 25G9.
[0094] In some embodiments, the antibody consists of an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0095] In another aspect, provided herein is an isolated antibody that competes for binding to human TF with the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.
[0096] In some embodiments, the antibody is a human antibody, a humanized antibody, or a chimeric antibody.
[0097] In some embodiments, the antibody inhibits FVIIa-dependent TF signaling.
[0098] In some embodiments, the antibody binds to cynomolgus monkey TF.
[0099] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0100] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 78 to 93 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 98 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0101] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 78 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0102] In some embodiments, the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 78 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 85 and 92 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0103] In some embodiments, the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; and the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 78 to 93 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 98 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810.
[0104] In some embodiments, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay, the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF of the sequence set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence set forth in SEQ ID NO: 810; the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 78 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 112 of the extracellular domain of rat TF of the sequence set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence set forth in SEQ ID NO: 810; and wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 78 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 112 of the extracellular domain of rat TF of the sequence set forth in SEQ ID NO: The binding between the isolated antibody and the extracellular domain of rat TF with the sequence set forth in SEQ ID NO:838 (with substitutions of amino acid residues 77 to 85 and 92 to 112) was greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO:810.
[0105] In some embodiments, the antibody comprises all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, the antibody designated 43Ea, or the antibody designated 54E. In some embodiments, the three heavy chain CDRs and the three light chain CDRs are identified using Kabat, Chothia, AbM, Contact, or IMGT numbering.
[0106] In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 1F. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 1G. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 29D. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 29E. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 39A. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 54E.
[0107] In some embodiments, the antibody comprises V of SEQ ID NO: 37. H Sequence and V of SEQ ID NO:38 L In some embodiments, the antibody comprises V of SEQ ID NO: 75. H Sequence and V of SEQ ID NO:76 L In some embodiments, the antibody comprises V of SEQ ID NO: 341. H Sequence and V of SEQ ID NO:342 L In some embodiments, the antibody comprises V of SEQ ID NO: 379. H Sequence and V of SEQ ID NO: 380 L In some embodiments, the antibody comprises V of SEQ ID NO: 417. H Sequence and V of SEQ ID NO:418 L In some embodiments, the antibody comprises a V sequence of SEQ ID NO: 759. H Sequence and V of SEQ ID NO:760 L sequence.
[0108] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:773; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:774; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:775; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:776; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:777; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:778. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:785; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:786; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:787; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:788; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:789; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:790. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:791; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:796. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:808.
[0109] In some embodiments, the antibody comprises V of SEQ ID NO: 761. H Sequence and V of SEQ ID NO:762 L In some embodiments, the antibody comprises V of SEQ ID NO: 765. H Sequence and V of SEQ ID NO:766 L In some embodiments, the antibody comprises V of SEQ ID NO: 767. HSequence and V of SEQ ID NO:768 L In some embodiments, the antibody comprises V of SEQ ID NO: 771. H Sequence and V of SEQ ID NO: 772 L sequence.
[0110] In some embodiments, the antibody comprises: an antibody designated 1F, an antibody designated 1G, an antibody designated 29D, an antibody designated 29E, an antibody designated 39A, or an antibody designated 54E.
[0111] In some embodiments, the antibody consists of the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.
[0112] In another aspect, provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:773; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:774; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:775; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:776; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:777; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:778.
[0113] In another aspect, provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 784.
[0114] In another aspect, provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 785; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 786; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 787; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 788; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 789; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 790.
[0115] In another aspect, provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 791; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 796.
[0116] In another aspect, provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 802.
[0117] In another aspect, provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 808.
[0118] In another aspect, provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 877.
[0119] In another aspect, provided herein is an isolated antibody comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 883.
[0120] In some embodiments, the antibody has a K of less than or equal to 50 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, or 0.1 nM as measured by Octet QK384 or Biacore assay. D Binds to human TF.
[0121] In some embodiments, the antibody is a monoclonal antibody.
[0122] In some embodiments, the antibodies are multispecific.
[0123] In some embodiments, the antibody is a Fab, Fab', F(ab')2, Fv, scFv, (scFv)2, a single chain antibody molecule, a dual variable domain antibody, a single variable domain antibody, a linear antibody, or a V domain antibody.
[0124] In some embodiments, the antibody comprises a scaffold, optionally wherein the scaffold is an Fc, optionally a human Fc. In some embodiments, the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM. In some embodiments, the antibody comprises a heavy chain constant region of the IgG class and a subclass selected from IgG1, IgG2, IgG3, and IgG4. In some embodiments, the antibody comprises a heavy chain constant region of IgG1.
[0125] In some embodiments, the Fc comprises one or more modifications, wherein the one or more modifications result in increased half-life, increased antibody-dependent cellular cytotoxicity (ADCC), increased antibody-dependent cellular phagocytosis (ADCP), increased complement-dependent cytotoxicity (CDC), or decreased effector function compared to an Fc without the one or more modifications.
[0126] In another aspect, provided herein is an isolated antibody that competes with any of the antibodies described above for binding to human TF.
[0127] In another aspect, provided herein is an isolated antibody that binds to an epitope of human TF bound by any of the antibodies described above.
[0128] In another aspect, provided herein are sequences encoding any of the above antibodies, their V H 、its V L , its light chain, its heavy chain, or its antigen binding portion, an isolated polynucleotide or a group of isolated polynucleotides.
[0129] In another aspect, provided herein is a vector or a set of vectors comprising a polynucleotide or a set of polynucleotides as described above.
[0130] In another aspect, provided herein is a host cell comprising the above-mentioned polynucleotide or group of polynucleotides or the above-mentioned vector or group of vectors.
[0131] In another aspect, provided herein is a method for producing an antibody, comprising expressing the antibody using the above-mentioned host cell, and isolating the expressed antibody.
[0132] In another aspect, provided herein is a pharmaceutical composition comprising any of the antibodies described above and a pharmaceutically acceptable excipient.
[0133] In another aspect, provided herein is a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of any of the above antibodies or the above pharmaceutical composition.
[0134] In some embodiments, the disease or condition is cancer. In some embodiments, the cancer is head and neck cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is gastric cancer. In some embodiments, the cancer is esophageal cancer. In some embodiments, the cancer is cervical cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is triple negative breast cancer, which is estrogen receptor negative (ER-), progesterone receptor negative (PR-), and HER2 negative (HER2-). In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is bladder cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is kidney cancer.
[0135] In some embodiments, the disease or disorder involves neovascularization. In some embodiments, the disease or disorder involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer. In some embodiments, the disease or disorder involves vascular inflammation.
[0136] In some embodiments, the method further comprises administering one or more additional therapeutic agents to the subject. In some embodiments, the additional therapeutic agent is formulated in the same pharmaceutical composition as the antibody. In some embodiments, the additional therapeutic agent is formulated in a different pharmaceutical composition than the antibody. In some embodiments, the additional therapeutic agent is administered before administering the antibody. In some embodiments, the additional therapeutic agent is administered after administering the antibody. In some embodiments, the additional therapeutic agent is administered simultaneously with the antibody.
[0137] In another aspect, provided herein is a method for detecting TF in a subject having or suspected of having a disease or disorder, the method comprising: (a) receiving a sample from the subject; and (b) detecting the presence or level of TF in the sample by contacting the sample with any of the antibodies described above.
[0138] In some embodiments, the disease or condition is cancer. In some embodiments, the cancer is head and neck cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is gastric cancer. In some embodiments, the cancer is esophageal cancer. In some embodiments, the cancer is cervical cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is triple negative breast cancer, which is estrogen receptor negative (ER-), progesterone receptor negative (PR-), and HER2 negative (HER2-). In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is bladder cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is kidney cancer.
[0139] In some embodiments, the disease or disorder involves neovascularization. In some embodiments, the disease or disorder involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer. In some embodiments, the disease or disorder involves vascular inflammation.
[0140] In another aspect, provided herein is a method of detecting TF in a subject having or suspected of having a disease or disorder, the method comprising: (a) administering any of the antibodies described above to the subject; and (b) detecting the presence or level of TF in the subject.
[0141] In some embodiments, the disease or condition is cancer. In another embodiment, the cancer is head and neck cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is gastric cancer. In some embodiments, the cancer is esophageal cancer. In some embodiments, the cancer is cervical cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is triple negative breast cancer, which is estrogen receptor negative (ER-), progesterone receptor negative (PR-), and HER2 negative (HER2-). In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is bladder cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is kidney cancer.
[0142] In some embodiments, the disease or disorder involves neovascularization. In some embodiments, the disease or disorder involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer. In some embodiments, the disease or disorder involves vascular inflammation.
[0143] In another aspect, provided herein is a kit comprising any of the above antibodies or the above pharmaceutical compositions and instructions for use.
[0144] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody binds to the extracellular domain of human tissue factor (TF) at a human TF binding site that is different from the human TF binding site bound by human FVIIa.
[0145] In some embodiments, (1) is combined with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 LThe antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA) compared to a reference antibody having the same sequence as that shown in SEQ ID NO: 810, and (2) the binding between the antibody and the extracellular domain of a variant TF comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay.
[0146] In some embodiments, (1) is combined with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The antibody inhibits human thrombin generation as determined by a thrombin generation assay (TGA) to a lesser extent than a reference antibody having the same sequence as that shown in FIG5 , and (2) the binding between the antibody and the extracellular domain of a variant TF comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay.
[0147] In some embodiments, (1) is combined with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The antibody is permissive to human thrombin generation as determined by a thrombin generation assay (TGA) to a greater extent than a reference antibody having the same sequence as that shown in FIG5 , and (2) the binding between the antibody and the extracellular domain of a variant TF comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0148] In some embodiments, (1) is combined with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The antibody inhibits human thrombin generation as determined by a thrombin generation assay (TGA) by a lesser amount than a reference antibody having the sequence set forth in SEQ ID NO: 810, and (2) the binding between the antibody and the extracellular domain of a variant TF comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay.
[0149] In some embodiments, (1) is combined with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The antibody allows human thrombin generation in a greater amount as determined by a thrombin generation assay (TGA) compared to a reference antibody having the sequence shown in SEQ ID NO: 810, and (2) the binding between the antibody and the extracellular domain of a variant TF comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay.
[0150] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784.
[0151] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877.
[0152] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883.
[0153] In some embodiments, the V comprising SEQ ID NO: 821H Sequence and V of SEQ ID NO:822 L The antibodies do not inhibit human thrombin generation as determined by a thrombin generation assay (TGA) compared to a reference antibody of the same sequence.
[0154] In some embodiments, the V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The antibodies inhibited human thrombin generation as determined by a thrombin generation assay (TGA) to a lesser extent than a reference antibody with the same sequence.
[0155] In some embodiments, the V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The antibodies are permissive to human thrombin generation as determined by a thrombin generation assay (TGA) to a greater extent than a reference antibody of the same sequence.
[0156] In some embodiments, the V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The antibodies inhibit human thrombin generation as determined by a thrombin generation assay (TGA) by a lesser amount than a reference antibody having the same sequence as that of the thrombinase inhibitor.
[0157] In some embodiments, the V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The antibodies allow human thrombin generation as determined by a thrombin generation assay (TGA) in greater amounts than a reference antibody of the same sequence.
[0158] In some embodiments, antibody does not suppress the human thrombin determined by thrombin generation assay (TGA) and generates. In some embodiments, compared with isotype control, antibody does not reduce the thrombin peak value (peak value IIa) on the thrombin generation curve. In some embodiments, compared with isotype control, antibody does not increase the time (ttPeak) from the start of measuring to the thrombin peak value on the thrombin generation curve. In some embodiments, compared with isotype control, antibody does not reduce the endogenous thrombin potential (ETP) determined by the area under the thrombin generation curve. In some embodiments, antibody allows the human thrombin determined by thrombin generation assay (TGA) to generate. In some embodiments, compared with isotype control, antibody keeps the thrombin peak value (peak value IIa) on the thrombin generation curve. In some embodiments, compared with isotype control, antibody keeps the time (ttPeak) from the start of measuring to the thrombin peak value on the thrombin generation curve. In some embodiments, compared with isotype control, antibody retains the endogenous thrombin potential (ETP) determined by the area under the thrombin generation curve.
[0159] In some embodiments, the antibody binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX.In some embodiments, the antibody does not interfere with the ability of TF:FVIIa to convert FX to FXa.
[0160] In some embodiments, the antibody does not compete with human FVIIa for binding to human TF.
[0161] In some embodiments, the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); allows human thrombin generation as determined by a thrombin generation assay (TGA); binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; does not interfere with the ability of TF:FVIIa to convert FX to FXa; and does not compete with FVIIa for binding to human TF.
[0162] In some embodiments, the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; allows human thrombin generation as determined by a thrombin generation assay (TGA); retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX; does not interfere with the ability of TF:FVIIa to convert FX to FXa; and does not compete with FVIIa for binding to human TF.
[0163] In some embodiments, the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); does not reduce the thrombin peak (Peak IIa) on the thrombin generation curve compared to an isotype control; does not increase the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to an isotype control; does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; allows human thrombin generation as determined by a thrombin generation assay (TGA); maintains the thrombin peak on the thrombin generation curve (Peak IIa) compared to the isotype control; maintains the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to the isotype control; retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to the isotype control; binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX; does not interfere with the ability of TF:FVIIa to convert FX to FXa; and does not compete with FVIIa for binding to human TF.
[0164] In some embodiments, the antibody inhibits FVIIa-dependent TF signaling.
[0165] In some embodiments, the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is K149N.
[0166] In some embodiments, the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is K68N.
[0167] In some embodiments, the binding between the antibody and the extracellular domain of a variant TF comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay. In some embodiments, the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 are N171H and T197K.
[0168] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 1 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 1 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0169] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 39 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 38 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0170] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0171] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 146 to 158 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 151 to 163 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0172] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 159 to 219 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 224 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0173] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 159 to 189 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 194 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0174] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 159 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0175] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 167 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 172 to 179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0176] In some embodiments, the binding between the antibody and the extracellular domain of rat TF (in which amino acid residues 141 to 194 of the sequence set forth in SEQ ID NO: 838 are substituted with amino acid residues 136 to 189 of the extracellular domain of human TF set forth in SEQ ID NO: 810) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0177] In some embodiments, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay, the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the antibody and the human TF extracellular domain (in which amino acid residues 1 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 1 to 76 of the rat TF extracellular domain set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; and the binding between the antibody and the human TF extracellular domain (in which amino acid residues 39 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 1 to 76 of the rat TF extracellular domain set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810. The binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 838 (in which amino acid residues 38 to 76 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838 are substituted) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 146 to 158 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 151 to 163 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the antibody and the extracellular domain of rat TF (in which amino acid residues 146 to 158 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 151 to 163 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; In some embodiments, the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810 (where amino acid residues 141 to 194 of the sequence set forth in SEQ ID NO: 838 are substituted with amino acid residues 136 to 189 of the extracellular domain of human TF having the sequence set forth in SEQ ID NO: 810) is greater than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is K149N; and the mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is K68N.
[0178] In some embodiments, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay, the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; and the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 1 to 77 of the sequence set forth in SEQ ID NO: 810 are replaced by SEQ ID NO: 810) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810. The binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 838 (in which amino acid residues 1 to 76 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838 are substituted) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 39 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 38 to 76 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF with the sequence set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810; the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 146 to 158 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues The binding between the antibody and the extracellular domain of TF (in which amino acid residues 151 to 163 of the extracellular domain of rat TF of the sequence set forth in SEQ ID NO: 838 are substituted) is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence set forth in SEQ ID NO: 810; the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 159 to 219 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 224 of the extracellular domain of rat TF of the sequence set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF of the sequence set forth in SEQ ID NO: 810;The binding between the antibody and the extracellular domain of human TF (in which amino acid residues 159 to 189 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 194 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 159 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 167 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 172 to 179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810. In some embodiments, the antibody binds to an extracellular domain of TF with the sequence set forth in SEQ ID NO: 810, wherein the binding between the antibody and the extracellular domain of rat TF (in which amino acid residues 141 to 194 of the sequence set forth in SEQ ID NO: 838 are substituted with amino acid residues 136 to 189 of the extracellular domain of human TF with the sequence set forth in SEQ ID NO: 810) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is K149N; the mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is K68N; and the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 are N171H and T197K.
[0179] In some embodiments, the antibody binds to cynomolgus monkey TF. In some embodiments, the antibody binds to mouse TF. In some embodiments, the antibody binds to rabbit TF. In some embodiments, the antibody binds to porcine TF.
[0180] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); and (b) binds to a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay, less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810. In some embodiments, the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 are N171H and T197K.
[0181] In some embodiments, the antibody: (a) allows for human thrombin generation as determined by a thrombin generation assay (TGA); and (b) binds to a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay, less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810. In some embodiments, the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 are N171H and T197K.
[0182] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; and (c) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO:810 are N171H and T197K.
[0183] In some embodiments, the antibody: (a) permits human thrombin generation as determined by a thrombin generation assay (TGA); (b) binds to a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; and (c) binds to a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO:810 are N171H and T197K.
[0184] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) binds to cynomolgus monkey TF; (c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; and (d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO:810 are N171H and T197K.
[0185] In some embodiments, the antibody: (a) permits human thrombin generation as determined by a thrombin generation assay (TGA); (b) binds to cynomolgus monkey TF; (c) the binding between the antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; and (d) the binding between the antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay. In some embodiments, the mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO:810 is K149N; and the mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO:810 are N171H and T197K.
[0186] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) allows human thrombin generation as determined by a thrombin generation assay (TGA); (c) binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; (d) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (e) does not compete with FVIIa for binding to human TF; (f) inhibits FVIIa-dependent TF signaling; (g) binds to cynomolgus monkey TF; (h) binds to mouse TF; and (i) binds to rabbit TF.
[0187] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (c) allows human thrombin generation as determined by a thrombin generation assay (TGA); (d) retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; (f) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (g) does not compete with FVIIa for binding to human TF; (h) inhibits FVIIa-dependent TF signaling; (i) binds to cynomolgus monkey TF; (j) binds to mouse TF; and (k) binds to rabbit TF.
[0188] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the thrombin peak value (Peak IIa) on the thrombin generation curve compared to an isotype control; (c) does not increase the time from the start of the assay to the thrombin peak value on the thrombin generation curve (ttPeak) compared to an isotype control; (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by a thrombin generation assay (TGA); (f) maintains the thrombin peak value (Peak Il) on the thrombin generation curve compared to an isotype control. Ia); (g) retains the time from the start of the assay to the peak thrombin level on the thrombin generation curve (ttPeak) compared to an isotype control; (h) retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (i) binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (k) does not compete with FVIIa for binding to human TF; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus monkey TF; (n) binds to mouse TF; and (o) binds to rabbit TF.
[0189] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) allows human thrombin generation as determined by a thrombin generation assay (TGA); (c) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX; (d) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (e) does not compete with FVIIa for binding to human TF; (f) inhibits FVIIa-dependent TF signaling; (g) binds to cynomolgus monkey TF; (h) binds to mouse TF; (i) binds to rabbit TF; and (j) binds to porcine TF.
[0190] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (c) allows human thrombin generation as determined by a thrombin generation assay (TGA); (d) retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX; (f) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (g) does not compete with FVIIa for binding to human TF; (h) inhibits FVIIa-dependent TF signaling; (i) binds to cynomolgus monkey TF; (j) binds to mouse TF; (k) binds to rabbit TF; and (l) binds to porcine TF.
[0191] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the thrombin peak value (Peak IIa) on the thrombin generation curve compared to an isotype control; (c) does not increase the time from the start of the assay to the thrombin peak value on the thrombin generation curve (ttPeak) compared to an isotype control; (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by a thrombin generation assay (TGA); (f) maintains the thrombin peak value (Peak IIa) on the thrombin generation curve compared to an isotype control; g) preserves the time from the start of the assay to the peak thrombin level on the thrombin generation curve (ttPeak) compared to an isotype control; (h) preserves the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (i) binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (k) does not compete with FVIIa for binding to human TF; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus monkey TF; (n) binds to mouse TF; (o) binds to rabbit TF; and (p) binds to porcine TF.
[0192] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the thrombin peak value (peak IIa) on the thrombin generation curve compared to an isotype control; (c) does not increase the time from the start of the assay to the thrombin peak value on the thrombin generation curve (ttPeak) compared to an isotype control; (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by a thrombin generation assay (TGA); (f) maintains the thrombin peak value (peak IIa) on the thrombin generation curve compared to an isotype control; (g) maintains the time from the start of the assay to the thrombin generation curve compared to an isotype control. (h) retains endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (i) binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (k) does not compete with FVIIa for binding to human TF; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus monkey TF; (n) binds to mouse TF; (o) binds to rabbit TF; (p) binds to porcine TF; (q) binds to a fragment comprising SEQ ID NO: ... (r) the binding of the antibody to a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; (s) the binding of the antibody to a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay;(t) the binding of the antibody to the extracellular domain of human TF (in which amino acid residues 1 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 1 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; (u) the binding of the antibody to the extracellular domain of human TF (in which amino acid residues 39 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 38 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 10% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay (v) the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; (w) the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 146 to 158 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 151 to 163 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 10% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay (x) the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 159 to 219 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 224 of the rat TF extracellular domain set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;(y) the binding of the antibody to the extracellular domain of human TF (in which amino acid residues 159 to 189 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 194 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; (z) the binding of the antibody to the extracellular domain of human TF (in which amino acid residues 159 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 10% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay 810; (aa) the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 167 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 172 to 179 of the rat TF extracellular domain of SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; and (bb) the binding between the antibody and the extracellular domain of rat TF (in which amino acid residues 141 to 194 of the sequence set forth in SEQ ID NO: 838 are substituted with amino acid residues 136 to 189 of the human TF extracellular domain of SEQ ID NO: 810) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay;
[0193] In some embodiments, the antibody: (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); (b) does not reduce the thrombin peak value (peak IIa) on the thrombin generation curve compared to an isotype control; (c) does not increase the time from the start of the assay to the thrombin peak value on the thrombin generation curve (ttPeak) compared to an isotype control; (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (e) allows human thrombin generation as determined by a thrombin generation assay (TGA); (f) maintains the thrombin peak value (peak IIa) on the thrombin generation curve compared to an isotype control; (g) maintains the time from the start of the assay to the thrombin generation curve compared to an isotype control. (h) retains endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; (i) binds to human TF at a human TF binding site that is distinct from the human TF binding site bound by human FX; (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa; (k) does not compete with FVIIa for binding to human TF; (l) inhibits FVIIa-dependent TF signaling; (m) binds to cynomolgus monkey TF; (n) binds to mouse TF; (o) binds to rabbit TF; (p) binds to porcine TF; (q) binds to a fragment comprising SEQ ID NO: ... (r) the binding of the antibody to a variant TF extracellular domain comprising the mutation K68N of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; (s) the binding of the antibody to a variant TF extracellular domain comprising the mutations N171H and T197K of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay;(t) the binding of the antibody to the extracellular domain of human TF (in which amino acid residues 1 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 1 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; (u) the binding of the antibody to the extracellular domain of human TF (in which amino acid residues 39 to 77 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 38 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 10% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; (v) the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; (w) the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 146 to 158 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 151 to 163 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 10% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay (x) the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 159 to 219 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 224 of the rat TF extracellular domain set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;(y) the binding of the antibody to the extracellular domain of human TF (in which amino acid residues 159 to 189 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 194 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; (z) the binding of the antibody to the extracellular domain of human TF (in which amino acid residues 159 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 164 to 179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 10% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay 810; (aa) the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 167 to 174 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 172 to 179 of the rat TF extracellular domain of SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay; and (bb) the binding between the antibody and the extracellular domain of rat TF (in which amino acid residues 141 to 194 of the sequence set forth in SEQ ID NO: 838 are substituted with amino acid residues 136 to 189 of the human TF extracellular domain of SEQ ID NO: 810) is greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to the isotype control in a live cell staining assay;
[0194] In some embodiments, the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0195] In some embodiments, the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0196] In some embodiments, the antibody competes for binding to human TF with the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0197] In some embodiments, the antibody binds to the same epitope of human TF that is bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0198] In some embodiments, the antibody binds to the same epitope of human TF that is bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0199] In some embodiments, the antibody binds to the same epitope of human TF that is bound by the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0200] In some embodiments, the antibody comprises all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the following antibodies: the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea. In some embodiments, the three heavy chain CDRs and the three light chain CDRs are identified using Kabat, Chothia, AbM, Contact, or IMGT numbering.
[0201] In some embodiments, the antibody comprises all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0202] In some embodiments, the antibody comprises all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0203] In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5-T. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43B1. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43B7. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43D. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43D7. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43D8. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43E. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 43Ea.
[0204] In some embodiments, the antibody comprises V of SEQ ID NO: 113 H Sequence and V of SEQ ID NO: 114 L In some embodiments, the antibody comprises V of SEQ ID NO: 151. H Sequence and V of SEQ ID NO: 152 L In some embodiments, the antibody comprises a V sequence of SEQ ID NO: 189. H Sequence and V of SEQ ID NO: 190 L In some embodiments, the antibody comprises V of SEQ ID NO: 836. H Sequence and V of SEQ ID NO:837L In some embodiments, the antibody comprises a V sequence of SEQ ID NO: 227. H Sequence and V of SEQ ID NO: 228 L In some embodiments, the antibody comprises V of SEQ ID NO: 265. H Sequence and V of SEQ ID NO: 266 L In some embodiments, the antibody comprises V of SEQ ID NO: 303. H Sequence and V of SEQ ID NO:304 L In some embodiments, the antibody comprises V of SEQ ID NO: 455. H Sequence and V of SEQ ID NO:456 L In some embodiments, the antibody comprises V of SEQ ID NO: 493. H Sequence and V of SEQ ID NO: 494 L In some embodiments, the antibody comprises V of SEQ ID NO: 531. H Sequence and SEQ ID NO: 532 V L In some embodiments, the antibody comprises V of SEQ ID NO: 569. H Sequence and V of SEQ ID NO:570 L In some embodiments, the antibody comprises V of SEQ ID NO: 607. H Sequence and V of SEQ ID NO: 608 L In some embodiments, the antibody comprises V of SEQ ID NO: 645. H Sequence and V of SEQ ID NO: 646 L In some embodiments, the antibody comprises V of SEQ ID NO: 683. H Sequence and V of SEQ ID NO: 684 L In some embodiments, the antibody comprises V of SEQ ID NO: 721 H Sequence and V of SEQ ID NO:722 L sequence.
[0205] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802.
[0206] In some embodiments, the antibody comprises V of SEQ ID NO: 763. H Sequence and V of SEQ ID NO:764 L In some embodiments, the antibody comprises V of SEQ ID NO: 868. H Sequence and V of SEQ ID NO:869 L In some embodiments, the antibody comprises V of SEQ ID NO: 870 HSequence and V of SEQ ID NO:871 L In some embodiments, the antibody comprises V of SEQ ID NO: 769. H Sequence and V of SEQ ID NO: 770 L sequence.
[0207] In some embodiments, the antibodies include: an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, an antibody designated 25G9, an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea. In some embodiments, the antibodies include: an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, or an antibody designated 25G9. In some embodiments, the antibody comprises: an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0208] In some embodiments, the antibody consists of an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, an antibody designated 25G9, an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea. In some embodiments, the antibody consists of an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, or an antibody designated 25G9. In some embodiments, the antibody consists of an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0209] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody competes for binding to human TF with the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.
[0210] In some embodiments, the antibody inhibits FVIIa-dependent TF signaling.
[0211] In some embodiments, the antibody binds to cynomolgus monkey TF.
[0212] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0213] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 78 to 93 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 98 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0214] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 78 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0215] In some embodiments, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 78 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 85 and 92 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0216] In some embodiments, the binding of the antibody to the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; and the binding of the antibody to the extracellular domain of human TF (in which amino acid residues 78 to 93 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 98 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0217] In some embodiments, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay, the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 94 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 99 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 78 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; and the binding between the antibody and the extracellular domain of human TF (in which amino acid residues 78 to 107 of the sequence set forth in SEQ ID NO: 810 are substituted with amino acid residues 77 to 112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the antibody and the extracellular domain of TF set forth in SEQ ID NO: 810. The binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO:838 (with substitutions of amino acid residues 77 to 85 and 92 to 112) was greater than 50% of the binding between the antibody and the extracellular domain of TF with the sequence set forth in SEQ ID NO:810.
[0218] In some embodiments, the antibody comprises all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, the antibody designated 43Ea, or the antibody designated 54E. In some embodiments, the three heavy chain CDRs and the three light chain CDRs are identified using Kabat, Chothia, AbM, Contact, or IMGT numbering.
[0219] In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 1F. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 1G. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 29D. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 29E. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 39A. In some embodiments, the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated as 54E.
[0220] In some embodiments, the antibody comprises V of SEQ ID NO: 37 H Sequence and V of SEQ ID NO:38 L In some embodiments, the antibody comprises V of SEQ ID NO: 75. H Sequence and V of SEQ ID NO:76 L In some embodiments, the antibody comprises V of SEQ ID NO: 341. H Sequence and V of SEQ ID NO:342 L In some embodiments, the antibody comprises V of SEQ ID NO: 379. H Sequence and V of SEQ ID NO: 380 L In some embodiments, the antibody comprises V of SEQ ID NO: 417. H Sequence and V of SEQ ID NO:418 L In some embodiments, the antibody comprises a V sequence of SEQ ID NO: 759. H Sequence and V of SEQ ID NO:760 L sequence.
[0221] In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:773; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:774; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:775; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:776; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:777; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:778. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:785; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:786; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:787; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:788; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:789; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:790. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:791; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:796. In some embodiments, the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:808.
[0222] In some embodiments, the antibody comprises V of SEQ ID NO: 761. H Sequence and V of SEQ ID NO:762 L In some embodiments, the antibody comprises V of SEQ ID NO: 765. H Sequence and V of SEQ ID NO:766 L In some embodiments, the antibody comprises V of SEQ ID NO: 767. HSequence and V of SEQ ID NO:768 L In some embodiments, the antibody comprises V of SEQ ID NO: 771. H Sequence and V of SEQ ID NO: 772 L sequence.
[0223] In some embodiments, the antibody comprises: an antibody designated 1F, an antibody designated 1G, an antibody designated 29D, an antibody designated 29E, an antibody designated 39A, or an antibody designated 54E. In some embodiments, the antibody consists of: an antibody designated 1F, an antibody designated 1G, an antibody designated 29D, an antibody designated 29E, an antibody designated 39A, or an antibody designated 54E.
[0224] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 773; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 774; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 775; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 776; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 777; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 778.
[0225] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 784.
[0226] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 785; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 786; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 787; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 788; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 789; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 790.
[0227] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 791; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 796.
[0228] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 802.
[0229] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 808.
[0230] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 877.
[0231] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 883.
[0232] In some embodiments, the antibody is a human antibody, a humanized antibody, or a chimeric antibody.
[0233] In some embodiments, the antibody has a K of less than or equal to 50 nM, 10 nM, 5 nM, 1 nM, 0.5 nM, or 0.1 nM as measured by Octet QK384 or Biacore assay. D Binds to human TF.
[0234] In some embodiments, the antibody is a monoclonal antibody.
[0235] In some embodiments, the antibodies are multispecific.
[0236] In some embodiments, the antibody is a Fab, Fab', F(ab')2, Fv, scFv, (scFv)2, a single chain antibody molecule, a dual variable domain antibody, a single variable domain antibody, a linear antibody, or a V domain antibody.
[0237] In some embodiments, the antibody comprises a scaffold, optionally wherein the scaffold is Fc, optionally human Fc. In some embodiments, the antibody comprises a heavy chain constant region selected from the class of IgG, IgA, IgD, IgE and IgM. In some embodiments, the antibody comprises an IgG class and a heavy chain constant region selected from the subclass of IgG1, IgG2, IgG3 and IgG4. In some embodiments, the antibody comprises a heavy chain constant region of IgG1. In some embodiments, Fc comprises one or more modifications, wherein compared to an Fc not having one or more modifications, one or more modifications result in an increase in half-life, an increase in antibody-dependent cellular cytotoxicity (ADCC), an increase in antibody-dependent cellular phagocytosis (ADCP), an increase in complement-dependent cytotoxicity (CDC), or a decrease in effector function.
[0238] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody competes with any of the above antibodies for binding to human TF.
[0239] In another aspect, provided herein is an antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody binds to an epitope of human TF bound by any of the above antibodies.
[0240] In some embodiments, the cytotoxic agent comprises an anti-angiogenic agent, a pro-apoptotic agent, an anti-mitotic agent, an anti-kinase agent, an alkylating agent, a hormone, a hormone agonist, a hormone antagonist, a chemokine, a drug, a prodrug, a toxin, an enzyme, an antimetabolite, an antibiotic, an alkaloid, or a radioisotope. In some embodiments, the cytotoxic agent comprises at least one of calicheamycin, camptothecin, carboplatin, irinotecan, SN-38, carboplatin, camptothecin, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunorubicin, doxorubicin, doxorubicin, etoposide, idarubicin, topotecan, vinca alkaloid, maytansinoid, maytansinoid analog, pyrrolobenzodiazepine (pyrrolobenzodiazepine), taxanes, duocarmycin, dolastatin, and auristatin.
[0241] In some embodiments, the linker comprises a labile linker, an acid-labile linker, a photolabile linker, a charged linker, a disulfide-containing linker, a peptidase-sensitive linker, a b-glucuronide linker, a dimethyl linker, a thioether linker, or a hydrophilic linker. In some embodiments, the linker is a cleavable linker. In some embodiments, the linker is a non-cleavable linker.
[0242] In another aspect, provided herein is a pharmaceutical composition comprising any of the above-described antibody-drug conjugates and a pharmaceutically acceptable excipient.
[0243] In another aspect, provided herein is a method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of any of the above-described antibody-drug conjugates or the above-described pharmaceutical composition.
[0244] In some embodiments, the disease or condition is cancer. In some embodiments, the cancer is head and neck cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is gastric cancer. In some embodiments, the cancer is esophageal cancer. In some embodiments, the cancer is cervical cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is triple negative breast cancer, which is estrogen receptor negative (ER-), progesterone receptor negative (PR-), and HER2 negative (HER2-). In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is bladder cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is kidney cancer.
[0245] In some embodiments, the method further comprises administering one or more additional therapeutic agents to the subject. In some embodiments, the additional therapeutic agent is formulated in the same pharmaceutical composition as the antibody-drug conjugate. In some embodiments, the additional therapeutic agent is formulated in a different pharmaceutical composition than the antibody-drug conjugate. In some embodiments, the additional therapeutic agent is administered before administering the antibody-drug conjugate. In some embodiments, the additional therapeutic agent is administered after administering the antibody-drug conjugate. In some embodiments, the additional therapeutic agent is administered simultaneously with the antibody-drug conjugate.
[0246] In another aspect, provided herein is a method of detecting TF in a subject having or suspected of having a disease or disorder, the method comprising: (a) administering to the subject any of the above-described antibody-drug conjugates; and (b) detecting the presence or level of TF in the subject.
[0247] In some embodiments, the disease or condition is cancer. In some embodiments, the cancer is head and neck cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is gastric cancer. In some embodiments, the cancer is esophageal cancer. In some embodiments, the cancer is cervical cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is triple negative breast cancer, which is estrogen receptor negative (ER-), progesterone receptor negative (PR-), and HER2 negative (HER2-). In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is lung cancer. In some embodiments, the cancer is bladder cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is kidney cancer.
[0248] In another aspect, provided herein is a kit comprising any of the above-described antibody-drug conjugates or the above-described pharmaceutical compositions and instructions for use.
[0249] Specifically, the present invention relates to the following:
[0250] 1. An isolated human antibody that binds to the extracellular domain of human tissue factor (TF), wherein the antibody binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FVIIa.
[0251] 2. The isolated human antibody according to item 1, wherein
[0252] (1) with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA) compared to a reference antibody having a sequence
[0253] (2) the binding between the isolated antibody and the extracellular domain of a variant TF comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated and reconstituted antibody relative to an isotype control in a live cell staining assay.
[0254] 3. The isolated human antibody of item 1 or 2, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 784.
[0255] 4. The isolated human antibody of any one of items 1 to 3, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 877.
[0256] 5. The isolated human antibody of any one of items 1 to 3, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 883.
[0257] 6. The isolated human antibody of item 1, wherein the V sequence of the isolated human antibody comprises SEQ ID NO: 821. H Sequence and SEQ ID NO: 822 V L The isolated antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA) compared to a reference antibody having the same sequence as that of the antibody.
[0258] 7. The isolated human antibody of item 1, wherein the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA).
[0259] 8. The isolated human antibody of item 7, wherein the antibody does not reduce the thrombin peak (Peak IIa) on a thrombin generation curve compared to an isotype control.
[0260] 9. The isolated human antibody of item 7 or 8, wherein the antibody does not increase the time from the start of the assay to the thrombin peak (ttPeak) on the thrombin generation curve compared to an isotype control.
[0261] 10. The isolated human antibody of any one of items 7 to 9, wherein the antibody does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control.
[0262] 11. The isolated human antibody of any one of the above items, wherein the antibody allows human thrombin generation as determined by thrombin generation assay (TGA).
[0263] 12. The isolated human antibody of item 11, wherein the antibody retains the thrombin peak (Peak IIa) on the thrombin generation curve compared to an isotype control.
[0264] 13. The isolated human antibody of item 11 or 12, wherein the antibody retains the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to an isotype control.
[0265] 14. The isolated human antibody of any one of items 11 to 13, wherein the antibody retains endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control.
[0266] 15. The isolated human antibody of any one of the above items, wherein the antibody binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX.
[0267] 16. The isolated human antibody of any one of the above items, wherein the antibody does not interfere with the ability of TF:FVIIa to convert FX to FXa.
[0268] 17. The isolated human antibody of any one of the above items, wherein the antibody does not compete with human FVIIa for binding to human TF.
[0269] 18. An isolated human antibody as described in any of the above items, wherein the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); allows human thrombin generation as determined by a thrombin generation assay (TGA); binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX; does not interfere with the ability of TF:FVIIa to convert FX to FXa; and does not compete with FVIIa for binding to human TF.
[0270] 19. An isolated human antibody as described in any of the above items, wherein the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; allows human thrombin generation as determined by a thrombin generation assay (TGA); retains the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX; does not interfere with the ability of TF:FVIIa to convert FX to FXa; and does not compete with FVIIa for binding to human TF.
[0271] 20. The isolated human antibody of any one of the above items, wherein the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); does not reduce the thrombin peak (peak IIa) on the thrombin generation curve compared to an isotype control; does not increase the time (ttPeak) from the start of the assay to the thrombin peak on the thrombin generation curve compared to an isotype control; does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control; allows human thrombin generation as determined by a thrombin generation assay (TGA) to be generated. thrombin generation; maintaining the thrombin peak on the thrombin generation curve (Peak IIa) as compared to an isotype control; maintaining the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) as compared to an isotype control; retaining the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve as compared to an isotype control; binding to human TF at a human TF binding site that is different from the human TF binding site bound by human FX; not interfering with the ability of TF:FVIIa to convert FX to FXa; and not competing with FVIIa for binding to human TF.
[0272] 21. The isolated human antibody of any one of the above items, wherein the antibody inhibits FVIIa-dependent TF signaling.
[0273] 22. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF having the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0274] 23. The isolated human antibody of item 22, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is K149N.
[0275] 24. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence shown in SEQ ID NO: 810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0276] 25. The isolated human antibody of item 24, wherein the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO: 810 is K68N.
[0277] 26. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0278] 27. The isolated human antibody of item 26, wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 are N171H and T197K.
[0279] 28. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 1-77 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 1-76 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0280] 29. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 39-77 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 38-76 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0281] 30. The isolated human antibody of any one of the preceding items, wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 94-107 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 99-112 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0282] 31. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 146-158 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 151-163 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0283] 32. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159-219 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 164-224 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0284] 33. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159-189 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 164-194 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0285] 34. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159-174 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 164-179 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0286] 35. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 167-174 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 172-179 of the rat TF extracellular domain shown in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0287] 36. The isolated human antibody of any one of the above items, wherein the binding between the isolated antibody and the extracellular domain of rat TF (in which amino acid residues 141-194 of the sequence shown in SEQ ID NO: 838 are replaced by amino acid residues 136-189 of the extracellular domain of human TF shown in SEQ ID NO: 810) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0288] 37. The isolated human antibody of any one of the preceding items, wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;
[0289] wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810;
[0290] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 1-77 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 1-76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0291] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 39-77 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 38-76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0292] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 94-107 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 99-112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0293] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 146-158 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 151-163 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; and
[0294] wherein the binding between the isolated antibody and the extracellular domain of rat TF (in which amino acid residues 141-194 of the sequence shown in SEQ ID NO: 838 are replaced by amino acid residues 136-189 of the extracellular domain of human TF shown in SEQ ID NO: 810) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810.
[0295] 38. The isolated human antibody of item 37, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is K149N; and
[0296] The mutation at amino acid residue 68 of the sequence shown in SEQ ID NO: 810 is K68N.
[0297] 39. The isolated human antibody of any one of the preceding items, wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay;
[0298] wherein the binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810;
[0299] wherein the binding between the isolated antibody and a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0300] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 1-77 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 1-76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0301] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 39-77 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 38-76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0302] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 94-107 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 99-112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0303] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 146-158 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 151-163 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0304] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159-219 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 164-224 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0305] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159-189 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 164-194 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0306] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 159-174 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 164-179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810;
[0307] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 167-174 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 172-179 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; and
[0308] wherein the binding between the isolated antibody and the extracellular domain of rat TF (in which amino acid residues 141-194 of the sequence shown in SEQ ID NO: 838 are replaced by amino acid residues 136-189 of the extracellular domain of human TF shown in SEQ ID NO: 810) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810.
[0309] 40. The isolated human antibody of item 39, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is K149N;
[0310] wherein the mutation at amino acid residue 68 of the sequence shown in SEQ ID NO: 810 is K68N; and
[0311] The mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 are N171H and T197K.
[0312] 41. The isolated human antibody of any one of the above items, wherein the antibody binds to cynomolgus monkey TF.
[0313] 42. The isolated human antibody of any one of the above items, wherein the antibody binds to mouse TF.
[0314] 43. The isolated human antibody of any one of the above items, wherein the antibody binds to rabbit TF.
[0315] 44. The isolated human antibody of any one of the above items, wherein the antibody binds to porcine TF.
[0316] 45. The isolated human antibody of any one of the above items, wherein the antibody reduces lesion size in a porcine choroidal neovascularization (CNV) model.
[0317] 46. The isolated human antibody of any one of the above items, wherein the antibody:
[0318] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA); and
[0319] (b) the binding of the antibody to the extracellular domain of a variant TF comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0320] 47. The isolated human antibody of item 46, wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 are N171H and T197K.
[0321] 48. The isolated human antibody of any one of the above items, wherein the antibody:
[0322] (a) allowing human thrombin generation as determined by a thrombin generation assay (TGA); and
[0323] (b) the binding of the antibody to the extracellular domain of a variant TF comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0324] 49. The isolated human antibody of item 48, wherein the mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 are N171H and T197K.
[0325] 50. The isolated human antibody of any one of the above items, wherein the antibody:
[0326] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA);
[0327] (b) the binding of the antibody to a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and
[0328] (c) the binding of the antibody to the extracellular domain of a variant TF comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0329] 51. The isolated human antibody of item 50, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is K149N; and
[0330] The mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 are N171H and T197K.
[0331] 52. The isolated human antibody of any one of the above items, wherein the antibody:
[0332] (a) allowing human thrombin generation as determined by a thrombin generation assay (TGA);
[0333] (b) the binding of the antibody to a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and
[0334] (c) the binding of the antibody to the extracellular domain of a variant TF comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0335] 53. The isolated human antibody of item 52, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is K149N; and
[0336] The mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 are N171H and T197K.
[0337] 54. The isolated human antibody of any one of the above items, wherein the antibody:
[0338] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA);
[0339] (b) binds to cynomolgus monkey TF;
[0340] (c) the binding of the antibody to a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and
[0341] (d) the binding of the antibody to the extracellular domain of a variant TF comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0342] 55. The isolated human antibody of item 54, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is K149N; and
[0343] The mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 are N171H and T197K.
[0344] 56. The isolated human antibody of any one of the above items, wherein the antibody:
[0345] (a) allowing human thrombin generation as determined by a thrombin generation assay (TGA);
[0346] (b) binds to cynomolgus monkey TF;
[0347] (c) the binding of the antibody to a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay; and
[0348] (d) the binding of the antibody to the extracellular domain of a variant TF comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0349] 57. The isolated human antibody of item 56, wherein the mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is K149N; and
[0350] The mutations at amino acid residues 171 and 197 of the sequence shown in SEQ ID NO: 810 are N171H and T197K.
[0351] 58. The isolated human antibody of any one of the above items, wherein the antibody:
[0352] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA);
[0353] (b) allowing human thrombin generation as determined by a thrombin generation assay (TGA);
[0354] (c) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX;
[0355] (d) does not interfere with the ability of TF:FVIIa to convert FX to FXa;
[0356] (e) does not compete with FVIIa for binding to human TF;
[0357] (f) inhibiting FVIIa-dependent TF signaling;
[0358] (g) binds to cynomolgus monkey TF;
[0359] (h) binds to mouse TF; and
[0360] (i) Binding to rabbit TF.
[0361] 59. The isolated human antibody of any one of the above items, wherein the antibody:
[0362] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA);
[0363] (b) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0364] (c) allowing human thrombin generation as determined by thrombin generation assay (TGA);
[0365] (d) retention of endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0366] (e) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX;
[0367] (f) does not interfere with the ability of TF:FVIIa to convert FX to FXa;
[0368] (g) does not compete with FVIIa for binding to human TF;
[0369] (h) inhibiting FVIIa-dependent TF signaling;
[0370] (i) Binding to cynomolgus monkey TF;
[0371] (j) binds to mouse TF; and
[0372] (k) Binding to rabbit TF.
[0373] 60. The isolated human antibody of any one of the above items, wherein the antibody:
[0374] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA);
[0375] (b) does not reduce the thrombin peak (peak IIa) on the thrombin generation curve compared to the isotype control;
[0376] (c) does not increase the time from the start of the assay to the thrombin peak (ttPeak) on the thrombin generation curve compared to an isotype control;
[0377] (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0378] (e) allowing human thrombin generation as determined by thrombin generation assay (TGA);
[0379] (f) The thrombin peak (peak IIa) on the thrombin generation curve was maintained compared with the isotype control;
[0380] (g) the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to an isotype control;
[0381] (h) retention of endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0382] (i) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX;
[0383] (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa;
[0384] (k) does not compete with FVIIa for binding to human TF;
[0385] (1) Inhibition of FVIIa-dependent TF signaling;
[0386] (m) binds to cynomolgus monkey TF;
[0387] (n) binds to mouse TF; and
[0388] (o) Binding to rabbit TF.
[0389] 61. The isolated human antibody of any one of the above items, wherein the antibody:
[0390] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA);
[0391] (b) allowing human thrombin generation as determined by a thrombin generation assay (TGA);
[0392] (c) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX;
[0393] (d) does not interfere with the ability of TF:FVIIa to convert FX to FXa;
[0394] (e) does not compete with FVIIa for binding to human TF;
[0395] (f) inhibiting FVIIa-dependent TF signaling;
[0396] (g) binds to cynomolgus monkey TF;
[0397] (h) binds to mouse TF;
[0398] (i) Binding to rabbit TF;
[0399] (j) binds to porcine TF;
[0400] and (k) reduced lesion size in a porcine choroidal neovascularization (CNV) model.
[0401] 62. The isolated human antibody of any one of the above items, wherein the antibody:
[0402] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA);
[0403] (b) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0404] (c) allowing human thrombin generation as determined by thrombin generation assay (TGA);
[0405] (d) retention of endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0406] (e) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX;
[0407] (f) does not interfere with the ability of TF:FVIIa to convert FX to FXa;
[0408] (g) does not compete with FVIIa for binding to human TF;
[0409] (h) inhibiting FVIIa-dependent TF signaling;
[0410] (i) Binding to cynomolgus monkey TF;
[0411] (j) binds to mouse TF;
[0412] (k) binds to rabbit TF;
[0413] (l) binds to porcine TF;
[0414] and (m) reduced lesion size in a porcine choroidal neovascularization (CNV) model.
[0415] 63. The isolated human antibody of any one of the above items, wherein the antibody:
[0416] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA);
[0417] (b) does not reduce the thrombin peak (peak IIa) on the thrombin generation curve compared to the isotype control;
[0418] (c) does not increase the time from the start of the assay to the thrombin peak (ttPeak) on the thrombin generation curve compared to an isotype control;
[0419] (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0420] (e) allowing human thrombin generation as determined by thrombin generation assay (TGA);
[0421] (f) The thrombin peak (peak IIa) on the thrombin generation curve was maintained compared with the isotype control;
[0422] (g) the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to an isotype control;
[0423] (h) retention of endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0424] (i) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX;
[0425] (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa;
[0426] (k) does not compete with FVIIa for binding to human TF;
[0427] (1) Inhibition of FVIIa-dependent TF signaling;
[0428] (m) binds to cynomolgus monkey TF;
[0429] (n) binds to mouse TF;
[0430] (o) binding to rabbit TF;
[0431] (p) binds to porcine TF;
[0432] and (q) reduced lesion size in a porcine choroidal neovascularization (CNV) model.
[0433] 64. The isolated human antibody of any one of the above items, wherein the antibody:
[0434] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA);
[0435] (b) does not reduce the thrombin peak (peak IIa) on the thrombin generation curve compared to the isotype control;
[0436] (c) does not increase the time from the start of the assay to the thrombin peak (ttPeak) on the thrombin generation curve compared to an isotype control;
[0437] (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0438] (e) allowing human thrombin generation as determined by thrombin generation assay (TGA);
[0439] (f) The thrombin peak (peak IIa) on the thrombin generation curve was maintained compared with the isotype control;
[0440] (g) the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to an isotype control;
[0441] (h) retention of endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0442] (i) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX;
[0443] (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa;
[0444] (k) does not compete with FVIIa for binding to human TF;
[0445] (1) Inhibition of FVIIa-dependent TF signaling;
[0446] (m) binds to cynomolgus monkey TF;
[0447] (n) binds to mouse TF;
[0448] (o) binding to rabbit TF;
[0449] (p) binds to porcine TF;
[0450] (q) reduced lesion size in a porcine choroidal neovascularization (CNV) model;
[0451] (r) wherein the binding of the isolated antibody to a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0452] (s) wherein the binding of the isolated antibody to a variant TF extracellular domain comprising a mutation at amino acid residue 68 of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0453] (t) wherein the binding of the isolated antibody to a variant TF extracellular domain comprising mutations at amino acid residues 171 and 197 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0454] (u) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 1-77 of the sequence set forth in SEQ ID NO: 810 are replaced with amino acid residues 1-76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0455] (v) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 39-77 of the sequence set forth in SEQ ID NO:810 are replaced with amino acid residues 38-76 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is greater than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0456] (w) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 94-107 of the sequence set forth in SEQ ID NO:810 are replaced by amino acid residues 99-112 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is greater than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0457] (x) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 146-158 of the sequence set forth in SEQ ID NO:810 are replaced with amino acid residues 151-163 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0458] (y) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 159-219 of the sequence set forth in SEQ ID NO:810 are replaced by amino acid residues 164-224 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0459] (z) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 159-189 of the sequence set forth in SEQ ID NO:810 are replaced with amino acid residues 164-194 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0460] (aa) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 159-174 of the sequence set forth in SEQ ID NO:810 are replaced with amino acid residues 164-179 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0461] (bb) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 167-174 of the sequence set forth in SEQ ID NO:810 are replaced by amino acid residues 172-179 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; and
[0462] (cc) wherein the binding of the isolated antibody to the extracellular domain of rat TF (in which amino acid residues 141-194 of the sequence set forth in SEQ ID NO:838 are replaced by amino acid residues 136-189 of the extracellular domain of human TF set forth in SEQ ID NO:810) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0463] 65. The isolated human antibody of any one of the above items, wherein the antibody:
[0464] (a) does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA);
[0465] (b) does not reduce the thrombin peak (peak IIa) on the thrombin generation curve compared to the isotype control;
[0466] (c) does not increase the time from the start of the assay to the thrombin peak (ttPeak) on the thrombin generation curve compared to an isotype control;
[0467] (d) does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0468] (e) allowing human thrombin generation as determined by thrombin generation assay (TGA);
[0469] (f) The thrombin peak (peak IIa) on the thrombin generation curve was maintained compared with the isotype control;
[0470] (g) the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to an isotype control;
[0471] (h) retention of endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control;
[0472] (i) binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FX;
[0473] (j) does not interfere with the ability of TF:FVIIa to convert FX to FXa;
[0474] (k) does not compete with FVIIa for binding to human TF;
[0475] (1) Inhibition of FVIIa-dependent TF signaling;
[0476] (m) binds to cynomolgus monkey TF;
[0477] (n) binds to mouse TF;
[0478] (o) binding to rabbit TF;
[0479] (p) binds to porcine TF;
[0480] (q) reduced lesion size in a porcine choroidal neovascularization (CNV) model;
[0481] (r) wherein the binding between the isolated antibody and the variant TF extracellular domain comprising the mutation K149N of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0482] (s) wherein the binding of the isolated antibody to the variant TF extracellular domain comprising the mutation K68N of the sequence set forth in SEQ ID NO: 810 is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0483] (t) wherein the binding of the isolated antibody to the variant TF extracellular domain comprising the mutations N171H and T197K of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0484] (u) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 1-77 of the sequence set forth in SEQ ID NO: 810 are replaced with amino acid residues 1-76 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0485] (v) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 39-77 of the sequence set forth in SEQ ID NO:810 are replaced by amino acid residues 38 to 76 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is greater than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0486] (w) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 94-107 of the sequence set forth in SEQ ID NO:810 are replaced by amino acid residues 99-112 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is greater than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0487] (x) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 146-158 of the sequence set forth in SEQ ID NO:810 are replaced with amino acid residues 151-163 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0488] (y) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 159-219 of the sequence set forth in SEQ ID NO:810 are replaced by amino acid residues 164-224 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0489] (z) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 159-189 of the sequence set forth in SEQ ID NO:810 are replaced with amino acid residues 164-194 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0490] (aa) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 159-174 of the sequence set forth in SEQ ID NO:810 are replaced with amino acid residues 164-179 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0491] (bb) wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 167-174 of the sequence set forth in SEQ ID NO:810 are replaced by amino acid residues 172-179 of the extracellular domain of rat TF set forth in SEQ ID NO:838) is less than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; and
[0492] (cc) wherein the binding of the isolated antibody to the extracellular domain of rat TF (in which amino acid residues 141-194 of the sequence set forth in SEQ ID NO:838 are replaced by amino acid residues 136-189 of the extracellular domain of human TF set forth in SEQ ID NO:810) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO:810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0493] 66. The isolated human antibody of any one of the above items, wherein the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0494] 67. The isolated human antibody of item 64, wherein the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0495] 68. The isolated human antibody of item 64, wherein the antibody competes for binding to human TF with the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0496] 69. The isolated human antibody of any one of the above items, wherein the antibody binds to the same epitope of human TF as bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0497] 70. The isolated human antibody of item 69, wherein the antibody binds to the same epitope of human TF that is bound by the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0498] 71. The isolated human antibody of item 69, wherein the antibody binds to the same epitope of human TF that is bound by the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0499] 72. An isolated human antibody as described in any of the above items, wherein the isolated human antibody comprises all three heavy chain complementary determining regions (CDRs) and all three light chain CDRs from the following antibodies: the antibody designated as 25A, the antibody designated as 25A3, the antibody designated as 25A5, the antibody designated as 25A5-T, the antibody designated as 25G, the antibody designated as 25G1, the antibody designated as 25G9, the antibody designated as 43B, the antibody designated as 43B1, the antibody designated as 43B7, the antibody designated as 43D, the antibody designated as 43D7, the antibody designated as 43D8, the antibody designated as 43E, or the antibody designated as 43Ea.
[0500] 73. The isolated human antibody of item 72, wherein the three heavy chain CDRs and the three light chain CDRs are identified using Kabat, Chothia, AbM, Contact, or IMGT numbering.
[0501] 74. The isolated human antibody of item 72 or 73, wherein the isolated human antibody comprises all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0502] 75. The isolated human antibody of item 72 or 73, wherein the isolated human antibody comprises all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0503] 76. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A.
[0504] 77. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3.
[0505] 78. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5.
[0506] 79. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5-T.
[0507] 80. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G.
[0508] 81. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1.
[0509] 82. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9.
[0510] 83. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B.
[0511] 84. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B1.
[0512] 85. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B7.
[0513] 86. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D.
[0514] 87. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D7.
[0515] 88. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D8.
[0516] 89. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43E.
[0517] 90. The isolated human antibody of item 72 or 73, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43Ea.
[0518] 91. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 113. H Sequence and V of SEQ ID NO: 114 L sequence.
[0519] 92. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 151. H Sequence and V of SEQ ID NO: 152 L sequence.
[0520] 93. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 189. H Sequence and V of SEQ ID NO: 190 L sequence.
[0521] 94. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 836. H Sequence and V of SEQ ID NO:837 L sequence.
[0522] 95. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 227. H Sequence and V of SEQ ID NO: 228 L sequence.
[0523] 96. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 265. H Sequence and V of SEQ ID NO: 266 L sequence.
[0524] 97. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 303. H Sequence and V of SEQ ID NO:304 L sequence.
[0525] 98. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 455. H Sequence and V of SEQ ID NO:456 L sequence.
[0526] 99. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 493. H Sequence and V of SEQ ID NO: 494 L sequence.
[0527] 100. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 531. H Sequence and V of SEQ ID NO:532 L sequence.
[0528] 101. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 569. H Sequence and V of SEQ ID NO:570 L sequence.
[0529] 102. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 607. H Sequence and V of SEQ ID NO: 608 L sequence.
[0530] 103. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 645. H Sequence and V of SEQ ID NO: 646 L sequence.
[0531] 104. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 683. H Sequence and V of SEQ ID NO: 684 L sequence.
[0532] 105. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 721. H Sequence and V of SEQ ID NO:722 L sequence.
[0533] 106. The isolated human antibody of any one of items 1 to 73, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 784.
[0534] 107. The isolated human antibody of any one of items 1 to 73, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 877.
[0535] 108. The isolated human antibody of any one of items 1 to 73, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 883.
[0536] 109. The isolated human antibody of any one of items 1 to 73, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 802.
[0537] 110. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 763. H Sequence and V of SEQ ID NO:764 L sequence.
[0538] 111. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 868. H Sequence and V of SEQ ID NO:869 L sequence.
[0539] 112. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 870. H Sequence and V of SEQ ID NO:871 L sequence.
[0540] 113. An isolated human antibody as described in any one of items 1 to 73, wherein the antibody comprises a V sequence of SEQ ID NO: 769. H Sequence and V of SEQ ID NO: 770 L sequence.
[0541] 114. The isolated human antibody of any one of the above items, wherein the antibodies comprise: an antibody designated as 25A, an antibody designated as 25A3, an antibody designated as 25A5, an antibody designated as 25A5-T, an antibody designated as 25G, an antibody designated as 25G1, an antibody designated as 25G9, an antibody designated as 43B, an antibody designated as 43B1, an antibody designated as 43B7, an antibody designated as 43D, an antibody designated as 43D7, an antibody designated as 43D8, an antibody designated as 43E, or an antibody designated as 43Ea.
[0542] 115. The isolated human antibody of item 114, wherein the antibody comprises: an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, or an antibody designated 25G9.
[0543] 116. The isolated human antibody of item 114, wherein the antibody comprises: an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0544] 117. An isolated human antibody as described in any of the above items, wherein the antibody consists of the following: an antibody designated as 25A, an antibody designated as 25A3, an antibody designated as 25A5, an antibody designated as 25A5-T, an antibody designated as 25G, an antibody designated as 25G1, an antibody designated as 25G9, an antibody designated as 43B, an antibody designated as 43B1, an antibody designated as 43B7, an antibody designated as 43D, an antibody designated as 43D7, an antibody designated as 43D8, an antibody designated as 43E, or an antibody designated as 43Ea.
[0545] 118. The isolated human antibody of item 117, wherein the antibody consists of an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, or an antibody designated 25G9.
[0546] 119. The isolated human antibody of item 117, wherein the antibody consists of an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0547] 120. An isolated antibody comprising all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the following antibodies: antibody designated 25A, antibody designated 25A3, antibody designated 25A5, antibody designated 25A5-T, antibody designated 25G, antibody designated 25G1, antibody designated 25G9, antibody designated 43B, antibody designated 43B1, antibody designated 43B7, antibody designated 43D, antibody designated 43D7, antibody designated 43D8, antibody designated 43E, or antibody designated 43Ea.
[0548] 121. The isolated antibody of item 120, wherein the antibody is human, humanized or chimeric.
[0549] 122. The isolated antibody of item 120 or 121, wherein the three heavy chain CDRs and the three light chain CDRs are identified using Kabat, Chothia, AbM, Contact, or IMGT numbering.
[0550] 123. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0551] 124. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A.
[0552] 125. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A3.
[0553] 126. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5.
[0554] 127. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25A5-T.
[0555] 128. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G.
[0556] 129. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G1.
[0557] 130. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 25G9.
[0558] 131. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0559] 132. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B.
[0560] 133. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B.
[0561] 134. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43B7.
[0562] 135. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D.
[0563] 136. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D7.
[0564] 137. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43D8.
[0565] 138. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43E.
[0566] 139. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 43Ea.
[0567] 140. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 113. H Sequence and V of SEQ ID NO: 114 L sequence.
[0568] 141. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 151. H Sequence and V of SEQ ID NO: 152 L sequence.
[0569] 142. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 189. H Sequence and V of SEQ ID NO: 190 L sequence.
[0570] 143. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 836. H Sequence and V of SEQ ID NO:837 L sequence.
[0571] 144. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 227. H Sequence and V of SEQ ID NO: 228 L sequence.
[0572] 145. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 265. H Sequence and V of SEQ ID NO: 266 L sequence.
[0573] 146. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 303. H Sequence and V of SEQ ID NO:304 L sequence.
[0574] 147. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 455. H Sequence and V of SEQ ID NO:456 L sequence.
[0575] 148. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 493. H Sequence and V of SEQ ID NO: 494 L sequence.
[0576] 149. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 531. H Sequence and V of SEQ ID NO:532 L sequence.
[0577] 150. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 569. H Sequence and V of SEQ ID NO:570 L sequence.
[0578] 151. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 607. H Sequence and V of SEQ ID NO: 608 L sequence.
[0579] 152. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 645. H Sequence and V of SEQ ID NO: 646 L sequence.
[0580] 153. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 683. H Sequence and V of SEQ ID NO: 684 L sequence.
[0581] 154. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 721. H Sequence and V of SEQ ID NO:722 L sequence.
[0582] 155. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 784.
[0583] 156. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 877.
[0584] 157. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 883.
[0585] 158. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 802.
[0586] 159. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 763. H Sequence and V of SEQ ID NO:764 L sequence.
[0587] 160. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 868. H Sequence and V of SEQ ID NO:869 L sequence.
[0588] 161. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 870. H Sequence and V of SEQ ID NO:871 L sequence.
[0589] 162. The isolated antibody of any one of items 120 to 122, wherein the antibody comprises a V sequence of SEQ ID NO: 769. H Sequence and V of SEQ ID NO: 770 L sequence.
[0590] 163. The isolated antibody of any one of items 120 to 162, wherein the antibodies comprise: an antibody designated as 25A, an antibody designated as 25A3, an antibody designated as 25A5, an antibody designated as 25A5-T, an antibody designated as 25G, an antibody designated as 25G1, an antibody designated as 25G9, an antibody designated as 43B, an antibody designated as 43B1, an antibody designated as 43B7, an antibody designated as 43D, an antibody designated as 43D7, an antibody designated as 43D8, an antibody designated as 43E, or an antibody designated as 43Ea.
[0591] 164. The isolated antibody of any one of item 163, wherein the antibodies comprise: an antibody designated 25A, an antibody designated 25A3, an antibody designated 25A5, an antibody designated 25A5-T, an antibody designated 25G, an antibody designated 25G1, or an antibody designated 25G9.
[0592] 165. The isolated antibody of any one of item 163, wherein the antibody comprises: an antibody designated 43B, an antibody designated 43B1, an antibody designated 43B7, an antibody designated 43D, an antibody designated 43D7, an antibody designated 43D8, an antibody designated 43E, or an antibody designated 43Ea.
[0593] 166. The isolated antibody of any one of items 120 to 163, wherein the antibody consists of: an antibody designated as 25A, an antibody designated as 25A3, an antibody designated as 25A5, an antibody designated as 25A5-T, an antibody designated as 25G, an antibody designated as 25G1, an antibody designated as 25G9, an antibody designated as 43B, an antibody designated as 43B1, an antibody designated as 43B7, an antibody designated as 43D, an antibody designated as 43D7, an antibody designated as 43D8, an antibody designated as 43E, or an antibody designated as 43Ea.
[0594] 167. The isolated antibody of any one of item 166, wherein the antibody consists of the antibody designated 25A, the antibody designated 25A3, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.
[0595] 168. The isolated antibody of any one of item 166, wherein the antibody consists of the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.
[0596] 169. An isolated antibody that competes for binding to human TF with the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.
[0597] 170. The isolated antibody of item 169, wherein the antibody is human, humanized or chimeric.
[0598] 171. The isolated antibody of item 169 or 170, wherein the antibody inhibits FVIIa-dependent TF signaling.
[0599] 172. The isolated antibody of any one of items 169 to 171, wherein the antibody binds to cynomolgus monkey TF.
[0600] 173. The isolated antibody of any one of items 169 to 172, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 94-107 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 99-112 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0601] 174. The isolated antibody of any one of items 169 to 172, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 78-93 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 77-98 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to the isotype control in a live cell staining assay.
[0602] 175. The isolated antibody of any one of items 169 to 172, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 78-107 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 77-112 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0603] 176. The isolated antibody of any one of items 169 to 172, wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 78-107 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 77-85 and 92-112 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810 as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay.
[0604] 177. The isolated antibody of any one of items 169 to 172, wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 94-107 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 99-112 of the extracellular domain of rat TF shown in SEQ ID NO: 838) is greater than 50% of the binding of the isolated antibody to the extracellular domain of TF shown in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; and
[0605] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 78-93 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 77-98 of the rat TF extracellular domain shown in SEQ ID NO: 838) is less than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810.
[0606] 178. The isolated antibody of any one of items 169 to 172, wherein the binding of the isolated antibody to the extracellular domain of human TF (in which amino acid residues 94-107 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 99-112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding of the isolated antibody to the extracellular domain of TF set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay;
[0607] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 78-107 of the sequence set forth in SEQ ID NO: 810 are replaced by amino acid residues 77-112 of the extracellular domain of rat TF set forth in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF set forth in SEQ ID NO: 810; and
[0608] wherein the binding between the isolated antibody and the extracellular domain of human TF (in which amino acid residues 78-107 of the sequence shown in SEQ ID NO: 810 are replaced by amino acid residues 77-85 and 92-112 of the rat TF extracellular domain shown in SEQ ID NO: 838) is greater than 50% of the binding between the isolated antibody and the extracellular domain of TF shown in SEQ ID NO: 810.
[0609] 179. The isolated antibody of any one of items 169 to 178, comprising all three heavy chain complementarity determining regions (CDRs) and all three light chain CDRs from the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, the antibody designated 43Ea, or the antibody designated 54E.
[0610] 180. The isolated antibody of item 179, wherein the three heavy chain CDRs and the three light chain CDRs are identified using Kabat, Chothia, AbM, Contact, or IMGT numbering.
[0611] 181. The isolated antibody of item 179 or 180, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated IF.
[0612] 182. The isolated antibody of item 179 or 180, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 1G.
[0613] 183. The isolated antibody of item 179 or 180, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 29D.
[0614] 184. The isolated antibody of item 179 or 180, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 29E.
[0615] 185. The isolated antibody of item 179 or 180, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 39A.
[0616] 186. The isolated antibody of item 179 or 180, wherein the antibody comprises all three heavy chain CDRs and all three light chain CDRs from the antibody designated 54E.
[0617] 187. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises a V sequence of SEQ ID NO: 37. H Sequence and V of SEQ ID NO:38 L sequence.
[0618] 188. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises a V sequence of SEQ ID NO: 75.H Sequence and V of SEQ ID NO:76 L sequence.
[0619] 189. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises a V sequence of SEQ ID NO: 341. H Sequence and V of SEQ ID NO:342 L sequence.
[0620] 190. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises a V sequence of SEQ ID NO: 379. H Sequence and V of SEQ ID NO: 380 L sequence.
[0621] 191. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises a V sequence of SEQ ID NO: 417. H Sequence and V of SEQ ID NO:418 L sequence.
[0622] 192. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises a V sequence of SEQ ID NO: 759. H Sequence and V of SEQ ID NO:760 L sequence.
[0623] 193. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 773; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 774; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 775; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 776; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 777; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 778.
[0624] 194. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 785; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 786; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 787; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 788; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 789; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 790.
[0625] 195. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 791; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 792; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 793; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 794; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 795; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 796.
[0626] 196. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 803; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 804; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 805; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 806; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 807; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 808.
[0627] 197. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises a V sequence of SEQ ID NO: 761. H Sequence and V of SEQ ID NO:762 L sequence.
[0628] 198. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises a V sequence of SEQ ID NO: 765. H Sequence and V of SEQ ID NO:766 L sequence.
[0629] 199. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises a V sequence of SEQ ID NO: 767. H Sequence and V of SEQ ID NO:768 L sequence.
[0630] 200. The isolated antibody of any one of items 169 to 180, wherein the antibody comprises a V sequence of SEQ ID NO: 771. H Sequence and V of SEQ ID NO: 772 L sequence.
[0631] 201. The isolated antibody of any one of items 169 to 200, wherein the antibody comprises: the antibody designated as 1F, the antibody designated as 1G, the antibody designated as 29D, the antibody designated as 29E, the antibody designated as 39A, or the antibody designated as 54E.
[0632] 202. The isolated antibody of any one of items 169 to 201, wherein the antibody consists of the antibody designated 1F, the antibody designated 1G, the antibody designated 29D, the antibody designated 29E, the antibody designated 39A, or the antibody designated 54E.
[0633] 203. An isolated antibody, comprising: a VH-CDR1 comprising the sequence listed in SEQ ID NO:773; a VH-CDR2 comprising the sequence listed in SEQ ID NO:774; a VH-CDR3 comprising the sequence listed in SEQ ID NO:775; a VL-CDR1 comprising the sequence listed in SEQ ID NO:776; a VL-CDR2 comprising the sequence listed in SEQ ID NO:777; and a VL-CDR3 comprising the sequence listed in SEQ ID NO:778.
[0634] 204. An isolated antibody, comprising: a VH-CDR1 comprising the sequence listed in SEQ ID NO:779; a VH-CDR2 comprising the sequence listed in SEQ ID NO:780; a VH-CDR3 comprising the sequence listed in SEQ ID NO:781; a VL-CDR1 comprising the sequence listed in SEQ ID NO:782; a VL-CDR2 comprising the sequence listed in SEQ ID NO:783; and a VL-CDR3 comprising the sequence listed in SEQ ID NO:784.
[0635] 205. An isolated antibody, comprising: a VH-CDR1 comprising the sequence listed in SEQ ID NO:785; a VH-CDR2 comprising the sequence listed in SEQ ID NO:786; a VH-CDR3 comprising the sequence listed in SEQ ID NO:787; a VL-CDR1 comprising the sequence listed in SEQ ID NO:788; a VL-CDR2 comprising the sequence listed in SEQ ID NO:789; and a VL-CDR3 comprising the sequence listed in SEQ ID NO:790.
[0636] 206. An isolated antibody, comprising: a VH-CDR1 comprising the sequence listed in SEQ ID NO:791; a VH-CDR2 comprising the sequence listed in SEQ ID NO:792; a VH-CDR3 comprising the sequence listed in SEQ ID NO:793; a VL-CDR1 comprising the sequence listed in SEQ ID NO:794; a VL-CDR2 comprising the sequence listed in SEQ ID NO:795; and a VL-CDR3 comprising the sequence listed in SEQ ID NO:796.
[0637] 207. An isolated antibody, comprising: a VH-CDR1 comprising the sequence listed in SEQ ID NO:797; a VH-CDR2 comprising the sequence listed in SEQ ID NO:798; a VH-CDR3 comprising the sequence listed in SEQ ID NO:799; a VL-CDR1 comprising the sequence listed in SEQ ID NO:800; a VL-CDR2 comprising the sequence listed in SEQ ID NO:801; and a VL-CDR3 comprising the sequence listed in SEQ ID NO:802.
[0638] 208. An isolated antibody, comprising: a VH-CDR1 comprising the sequence listed in SEQ ID NO:803; a VH-CDR2 comprising the sequence listed in SEQ ID NO:804; a VH-CDR3 comprising the sequence listed in SEQ ID NO:805; a VL-CDR1 comprising the sequence listed in SEQ ID NO:806; a VL-CDR2 comprising the sequence listed in SEQ ID NO:807; and a VL-CDR3 comprising the sequence listed in SEQ ID NO:808.
[0639] 209. An isolated antibody, comprising: a VH-CDR1 comprising the sequence listed in SEQ ID NO:872; a VH-CDR2 comprising the sequence listed in SEQ ID NO:873; a VH-CDR3 comprising the sequence listed in SEQ ID NO:874; a VL-CDR1 comprising the sequence listed in SEQ ID NO:875; a VL-CDR2 comprising the sequence listed in SEQ ID NO:876; and a VL-CDR3 comprising the sequence listed in SEQ ID NO:877.
[0640] 210. An isolated antibody, comprising: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883.
[0641] 211. The isolated antibody of any one of the above, wherein the antibody has a K of less than or equal to 50 nM, 10 nM, 5 nM, 1 nM, 0.5 nM or 0.1 nM as measured by an Octet QK384 or Biacore assay. D Binds to human TF.
[0642] 212. The isolated antibody of any one of the above items, wherein the antibody is a monoclonal antibody.
[0643] 213. The isolated antibody of any one of the above items, wherein the antibody is multispecific.
[0644] 214. The isolated antibody of any one of the above items, wherein the antibody is a Fab, Fab', F(ab')2, Fv, scFv, (scFv)2, a single-chain antibody molecule, a dual variable domain antibody, a single variable domain antibody, a linear antibody, or a V domain antibody.
[0645] 215. The isolated antibody of any one of the above items, wherein the antibody comprises a scaffold, optionally, wherein the scaffold is Fc, optionally human Fc.
[0646] 216. The isolated antibody of item 215, wherein the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM.
[0647] 217. The isolated antibody of item 216, wherein the antibody comprises a heavy chain constant region of the IgG class and a subclass selected from IgG1, IgG2, IgG3, and IgG4.
[0648] 218. The isolated antibody of item 217, wherein the antibody comprises a heavy chain constant region of IgG1.
[0649] 219. The isolated antibody of any one of items 215 to 218, wherein the Fc comprises one or more modifications, wherein the one or more modifications result in increased half-life, increased antibody-dependent cellular cytotoxicity (ADCC), increased antibody-dependent cellular phagocytosis (ADCP), increased complement-dependent cytotoxicity (CDC), or reduced effector function compared to an Fc without the one or more modifications.
[0650] 220. An isolated antibody that competes with the antibody of any one of the above for binding to human TF.
[0651] 221. An isolated antibody that binds to the human TF epitope bound by the antibody of any one of the above.
[0652] 222. An isolated polynucleotide or a group of isolated polynucleotides encoding an antibody, V or V thereof as described in any one of the above items. H 、its V L , its light chain, its heavy chain, or an antigen-binding portion thereof.
[0653] 223. A vector or a set of vectors comprising the polynucleotide or the polynucleotide according to item 222.
[0654] 224. A host cell comprising a polynucleotide or a group of polynucleotides according to item 222 or a vector or a group of vectors according to item 223.
[0655] 225. A method for producing an antibody, the method comprising expressing the antibody using the host cell of item 224, and isolating the expressed antibody.
[0656] 226. A pharmaceutical composition comprising the antibody of any one of items 1 to 221 and a pharmaceutically acceptable excipient.
[0657] 227. A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of the antibody of any one of items 1 to 221 or the pharmaceutical composition of item 226.
[0658] 228. The method of item 227, wherein the disease or condition is cancer.
[0659] 229. The method of item 228, wherein the cancer is head and neck cancer.
[0660] 230. The method of item 228, wherein the cancer is ovarian cancer.
[0661] 231. The method of item 228, wherein the cancer is gastric cancer.
[0662] 232. The method of item 228, wherein the cancer is esophageal cancer.
[0663] 233. The method of item 228, wherein the cancer is cervical cancer.
[0664] 234. The method of item 228, wherein the cancer is prostate cancer.
[0665] 235. The method of item 228, wherein the cancer is pancreatic cancer.
[0666] 236. The method of item 228, wherein the cancer is estrogen receptor negative (ER-), progesterone receptor negative (PR-), and HER2 negative (HER2-) triple negative breast cancer.
[0667] 237. The method of item 228, wherein the cancer is glioblastoma.
[0668] 238. The method of item 228, wherein the cancer is lung cancer.
[0669] 239. The method of item 228, wherein the cancer is bladder cancer.
[0670] 240. The method of item 228, wherein the cancer is melanoma.
[0671] 241. The method of item 228, wherein the cancer is renal cancer.
[0672] 242. The method of item 227, wherein the disease or disorder involves neovascularization.
[0673] 243. The method of item 242, wherein the disease or condition involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer.
[0674] 244. The method of item 227, wherein the disease or disorder involves vascular inflammation.
[0675] 245. The method of any one of items 227 to 244, further comprising administering one or more additional therapeutic agents to the subject.
[0676] 246. The method of item 245, wherein the additional therapeutic agent is formulated in the same pharmaceutical composition as the antibody.
[0677] 247. The method of item 245, wherein the additional therapeutic agent is formulated in a different pharmaceutical composition than the antibody.
[0678] 248. The method of item 245, wherein the additional therapeutic agent is administered prior to administering the antibody.
[0679] 249. The method of item 245, wherein the additional therapeutic agent is administered after administration of the antibody.
[0680] 250. The method of item 245, wherein the additional therapeutic agent is administered concurrently with the antibody.
[0681] 251. A method for detecting TF in a subject having or suspected of having a disease or disorder, the method comprising: (a) receiving a sample from the subject; and (b) detecting the presence or level of TF in the sample by contacting the sample with the antibody of any one of items 1 to 221.
[0682] 252. The method of item 251, wherein the disease or condition is cancer.
[0683] 253. The method of item 252, wherein the cancer is head and neck cancer.
[0684] 254. The method of item 252, wherein the cancer is ovarian cancer.
[0685] 255. The method of item 252, wherein the cancer is gastric cancer.
[0686] 256. The method of item 252, wherein the cancer is esophageal cancer.
[0687] 257. The method of item 252, wherein the cancer is cervical cancer.
[0688] 258. The method of item 252, wherein the cancer is prostate cancer.
[0689] 259. The method of item 252, wherein the cancer is pancreatic cancer.
[0690] 260. The method of item 252, wherein the cancer is triple negative breast cancer that is estrogen receptor negative (ER-), progesterone receptor negative (PR-), and HER2 negative (HER2-).
[0691] 261. The method of item 252, wherein the cancer is glioblastoma.
[0692] 262. The method of item 252, wherein the cancer is lung cancer.
[0693] 263. The method of item 252, wherein the cancer is bladder cancer.
[0694] 264. The method of item 252, wherein the cancer is melanoma.
[0695] 265. The method of item 252, wherein the cancer is renal cancer.
[0696] 266. The method of item 251, wherein the disease or disorder involves neovascularization.
[0697] 267. The method of item 266, wherein the disease or condition involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer.
[0698] 268. The method of item 251, wherein the disease or condition involves vascular inflammation.
[0699] 269. A method for detecting TF in a subject having or suspected of having a disease or disorder, the method comprising: (a) administering to the subject the antibody of any one of items 1 to 221; and (b) detecting the presence or level of TF in the subject.
[0700] 270. The method of item 269, wherein the disease or condition is cancer.
[0701] 271. The method of item 270, wherein the cancer is head and neck cancer.
[0702] 272. The method of item 270, wherein the cancer is ovarian cancer.
[0703] 273. The method of item 270, wherein the cancer is gastric cancer.
[0704] 274. The method of item 270, wherein the cancer is esophageal cancer.
[0705] 275. The method of item 270, wherein the cancer is cervical cancer.
[0706] 276. The method of item 270, wherein the cancer is prostate cancer.
[0707] 277. The method of item 270, wherein the cancer is pancreatic cancer.
[0708] 278. The method of item 270, wherein the cancer is triple negative breast cancer that is estrogen receptor negative (ER-), progesterone receptor negative (PR-), and HER2 negative (HER2-).
[0709] 279. The method of item 270, wherein the cancer is glioblastoma.
[0710] 280. The method of item 270, wherein the cancer is lung cancer.
[0711] 281. The method of item 270, wherein the cancer is bladder cancer.
[0712] 282. The method of item 270, wherein the cancer is melanoma.
[0713] 283. The method of item 270, wherein the cancer is renal cancer.
[0714] 284. The method of item 269, wherein the disease or disorder involves neovascularization.
[0715] 285. The method of item 284, wherein the disease or condition involving neovascularization is age-related macular degeneration (AMD), diabetic retinopathy, or cancer.
[0716] 286. The method of item 269, wherein the disease or condition involves vascular inflammation.
[0717] 287. A kit comprising the antibody of any one of items 1 to 221 or the pharmaceutical composition of item 226 and instructions for use.
[0718] 288. An antibody-drug conjugate comprising: an anti-human tissue factor (anti-hTF) antibody, a cytotoxic agent linked to the antibody, and optionally a linker linking the antibody to the cytotoxic agent, wherein the antibody binds to the extracellular domain of human tissue factor (TF) at a human TF binding site that is different from the human TF binding site bound by human FVIIa.
[0719] 289. The antibody-drug conjugate of item 288, wherein
[0720] (1) with V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA) compared to a reference antibody having a sequence
[0721] (2) the binding between the antibody and the extracellular domain of a variant TF comprising a mutation at amino acid residue 149 of the sequence set forth in SEQ ID NO: 810 is less than 50% of the binding between the antibody and the extracellular domain of TF having the sequence set forth in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the antibody relative to an isotype control in a live cell staining assay.
[0722] 290. The antibody-drug conjugate of item 288 or 289, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 784.
[0723] 291. The antibody-drug conjugate of any one of items 288 to 290, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 877.
[0724] 292. The antibody-drug conjugate of any one of items 288 to 290, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO: 878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO: 879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO: 880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO: 881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO: 882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO: 883.
[0725] 293. The antibody-drug conjugate of item 288, wherein the conjugate is combined with a V comprising SEQ ID NO: 821. H Sequence and V of SEQ ID NO:822 L The antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA) compared to a reference antibody having the same sequence as that of the thrombinase inhibitor.
[0726] 294. The antibody-drug conjugate of item 288, wherein the antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA).
[0727] 295. The antibody-drug conjugate of item 294, wherein the antibody does not reduce the thrombin peak (Peak IIa) on the thrombin generation curve compared to an isotype control.
[0728] 296. The antibody-drug conjugate of item 294 or 295, wherein the antibody does not increase the time from the start of the assay to the thrombin peak (ttPeak) on the thrombin generation curve compared to an isotype control.
[0729] 297. The antibody-drug conjugate of any one of items 294 to 296, wherein the antibody does not reduce the intrinsic thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control.
[0730] 298. The antibody-drug conjugate of any one of items 288 to 297, wherein the antibody allows human thrombin generation as determined by a thrombin generation assay (TGA).
[0731] 299. The antibody-drug conjugate of item 298, wherein the antibody maintains the thrombin peak (Peak IIa) on the thrombin generation curve compared to an isotype control.
[0732] 300. The antibody-drug conjugate of item 298 or 299, wherein the antibody retains the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) as compared to an isotype control.
[0733] 301. The antibody-drug conjugate of any one of items 298 to 300, wherein the antibody retains endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control.
[0734] 302. The antibody-drug conjugate of any one of items 288 to ...
Claims
1. An isolated human antibody that binds to the extracellular domain of human tissue factor (TF), wherein the antibody binds to human TF at a human TF binding site that is different from the human TF binding site bound by human FVIIa.
2. The isolated human antibody of claim 1, wherein (1) and a V comprising SEQ ID NO: 821 H Sequence and V of SEQ ID NO:822 L The isolated antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA) compared to a reference antibody having a sequence (2) the binding between the isolated antibody and the variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO: 810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF with the sequence shown in SEQ ID NO: 810, as determined by the median fluorescence intensity value of the isolated and reconstituted antibody relative to the isotype control in a live cell staining assay.
3. The isolated human antibody of claim 1 or 2, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:
784.
4. An isolated human antibody as described in any one of claims 1 to 3, wherein the antibody comprises: a VH-CDR1 comprising the sequence listed in SEQ ID NO:872; a VH-CDR2 comprising the sequence listed in SEQ ID NO:873; a VH-CDR3 comprising the sequence listed in SEQ ID NO:874; a VL-CDR1 comprising the sequence listed in SEQ ID NO:875; a VL-CDR2 comprising the sequence listed in SEQ ID NO:876; and a VL-CDR3 comprising the sequence listed in SEQ ID NO:
877.
5. The isolated human antibody of any one of claims 1 to 3, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:
883.
6. The isolated human antibody of claim 1, wherein the V H Sequence and V of SEQ ID NO:822 L The isolated antibody does not inhibit human thrombin generation as determined by a thrombin generation assay (TGA) compared to a reference antibody having a sequence identical to that of the antibody.
7. The isolated human antibody according to claim 1, wherein The antibodies do not inhibit human thrombin generation as determined by thrombin generation assay (TGA).
8. The isolated human antibody of claim 7, wherein the antibody does not reduce the thrombin peak (Peak IIa) on the thrombin generation curve compared to an isotype control.
9. The isolated human antibody of claim 7 or 8, wherein the antibody does not increase the time from the start of the assay to the thrombin peak on the thrombin generation curve (ttPeak) compared to an isotype control.
10. The isolated human antibody of any one of claims 7 to 9, wherein the antibody does not reduce the endogenous thrombin potential (ETP) as determined by the area under the thrombin generation curve compared to an isotype control.
